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ABSTRACT
The body’s innate ability to produce an inflammatory response due to tissue
irritation or damage is essential for growth and survival. The inflammatory response can
be triggered by numerous stimuli, including physical trauma, inhalation of dangerous
debris (such as silica and asbestos), tobacco/alcohol consumption, microbiota, diet, and
other lifestyle stressors. In a well-orchestrated inflammatory response, the circulatory
system increases blood flow and capillary permeability in the inflamed area to deliver
nutrients, white blood cells, and inflammatory mediating molecules. However, a
dysregulated inflammatory response can lead to chronic inflammation. Emerging
evidence continues to frame oncostatin M (OSM) as a pro-inflammatory cytokine that
drives chronic inflammation. The overexpression of OSM has been implicated in the
maintenance of several chronic inflammatory diseases, such as rheumatoid arthritis,
inflammatory bowel disease, metabolic syndrome, systemic sclerosis, lupus, and many
different forms of cancer. Therefore, OSM presents itself as a potential therapeutic target.
To the best of our research group’s knowledge, no clinically approved drugs
inhibit OSM signaling. Therefore, 26 lead small molecule inhibitors (SMIs) were
generated by high-throughput virtual screening of ~1.65 million compounds targeting the
putative receptor binding site of OSM. Out of the 26 compounds subjected to an enzymelinked immunosorbent assay, SMI-8 was identified as one of the most potent inhibitors of
OSM signaling. However, the predicted toxicity and stereoselective synthesis of SMI-8
makes the compound a poor drug candidate. So, mono- and bisthiazole-based analogs of
viii

SMI-8 were designed and synthesized using five distinct synthetic pathways to produce a
total of 35 compounds. Enzyme-linked immunosorbent assay (ELISA) experiments and
Western blot assays were performed to determine the inhibitory activity of several of the
analogs. In addition, fluorescence quenching assays, differential scanning fluorimetry
experiments, and chemical shift perturbation experiments identified direct binding
properties of the SMIs.
ELISA experiments revealed that almost all the SMI-8 analogs tested effectively
decreased the amount of pSTAT3 expressed in T47D human breast cancer cells.
Tryptophan fluorescence quenching assays determined the dissociation constant (KD)
values of SMI-8 and a structurally similar analog, SMI-8S, which were 6 ± 1 μM, and 14
± 3 μM, respectively. Unfortunately, the fluorescence quenching assay could not be used
to study the binding affinity of other analogs, as they were found to fluoresce at the same
wavelength as the tryptophan residue of the OSM protein.
In an attempt to solve this problem, differential scanning fluorimetry (DSF)
experiments were used to determine the relative binding characteristics of the
compounds. The data obtained from the DSF experiments suggest that most of the
analogs tested bind to the unfolded state of OSM, as the ligands decrease the melting
temperature of the protein. In addition, a chemical shift perturbation (CSP) experiment
suggests that SMI-8S interacts with the amino acids Gln90, Arg91, and Leu 92 at the
putative receptor binding site of OSM. The data, findings, and research within this thesis
provide enough evidence to support the idea that SMIs can target OSM as a practical
approach to treating various chronic inflammatory diseases.
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CHAPTER ONE: INTRODUCTION
1.1 Overview of Chapter One
Acute inflammation is the body’s normal, healthy response to physical trauma and
foreign invaders. In contrast, chronic inflammation is characterized by slow, long-term
inflammation that can last months to years without resolve. Due to the societal and
economic burden, chronic inflammatory diseases pose a serious threat to humankind, and
therefore, it is necessary to understand what causes them. Evidence suggests that
oncostatin M has a role in upregulating inflammatory pathways that drive chronic
inflammatory diseases such as irritable bowel disease (IBD), rheumatoid arthritis (RA),
metastasis of breast cancer, and systemic sclerosis (SSc). Currently, no small molecule
inhibitors that target oncostatin M have been published. We hypothesize that a small
molecule inhibitor can be synthesized that selectively binds to the active site of
oncostatin M, thereby rendering it unable to signal.
1.2 A Brief Overview of Inflammation
1.2.1 Acute Inflammation
Inflammation is the natural, biological response to numerous damaging incidents:
physical trauma, foreign invaders/pathogens, toxic compounds, or autoimmune
responses. The acute inflammatory process consists of separate, antagonistic processes in
the body. The first step pertains to the initial inflammatory response to the stimuli where
cells are recruited to the area of damage; the latter step is the removal of damaged cells,
tissue, and perhaps foreign invaders.1 The first part is typically referred to as the initial
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response, and the latter part is commonly referred to as the resolution stage. A typical
acute inflammatory response lasts only a few days.2 Overall, the main objective of the
body during an immune response is to increase blood flow to the injured area in order to
deliver nutrients, as well as remove any injured or compromised tissue. The rest of this
section will discuss the basic mechanisms observed during an acute inflammatory
response.
Figure 1.1 outlines the acute inflammatory response in 3 basic steps. In panel 1,
histamine is released mainly by mast cells in response to a traumatic event.2 Once
released, histamine acts upon the H1-receptors of the vascular endothelial cells to cause
vasodilation, which widens the blood vessels to increase blood flow to tissues. In
addition, proteins known as cytokines are released by macrophages and other leukocytes.
Cytokines are low molecular weight proteins that are involved in mediating cell signaling
and inflammatory responses. As seen in panel 2, some cytokines can also act as
chemotactic factors, which means they can recruit leukocytes such as neutrophils and
monocytes to the specific site of damage through a process called chemotaxis.3 Panel 3
depicts the resolution stage, where tissue healing occurs and tissue homeostasis is
achieved.
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Figure 1.1

The acute inflammatory response

(1) Physical trauma, or foreign invaders signal the mast cells to release histamine, as well as signal for the release
of cytokines from macrophages. (2) White blood cells such as neutrophils, monocytes, and macrophages invade
the damaged tissue. (3) Once the tissue is healed, or the foreign invader is neutralized, cellular debris is
transported away from the injury site, and normal tissue function can resume.

In addition to releasing histamine, leukocytes also have a specific role in
identifying proteins and carbohydrates that are foreign to the body and releasing
inflammatory mediators such as cytokines. Leukocytes residing in the tissue and
circulating leukocytes can recognize damaged cells or foreign invaders using pattern
recognition receptors (PRRs). These PRRs directly or indirectly detect pathogenassociated molecular patterns (PAMPs). PAMPs include foreign structures, such as
proteins and nucleic acids, that belong to invading organisms.3 PRRs are typically found
in the cytosol or on the cell surface itself. In response to PAMPs, PRRs can trigger
activating transcription factors such as nuclear factor-kappa beta, activator protein-1,
cAMP element-response binding protein, CCAAT-enhancer-binding proteins, and
interferon regulatory factors. Once transcribed in the body, these factors can upregulate
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the production of cytokines.4 These small signaling proteins can then further drive the
inflammatory response by recruiting more leukocytes to the area of inflammation.
1.2.2 Chronic Inflammation
In contrast to acute inflammation, chronic inflammation is characterized by a
long-term inflammatory response that can last months to years.5 Figure 1.2 illustrates a
simplified example of chronic inflammation occurring in nerve tissue driven in part by
cytokines. In panel 1, resident macrophages can be seen secreting cytokines into the
tissue due to trauma. Afterward, panel 2 depicts other macrophages migrating into the
tissue space as a result of cytokine signaling. In contrast to acute inflammation, the
healing process is stalled at this point, and tissue remodeling fails to occur. Next, panel 3
shows that the newly recruited macrophages are releasing cytokines as well as growth
factors.6 Finally, panel 4 shows a hypothetical height of disease severity where long-term
resident macrophages are expressing a pro-inflammatory phenotype and resolution of the
wound has not occurred. The accumulation of macrophages at damaged tissue(s) is a
strong indicator of chronic inflammation due to their release of cytokines, chemokines,
and growth factors.6-9
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Figure 1.2

Cytokines maintain chronic inflammation

(1) Upon initial injury, resident macrophages and other leukocytes release pro-inflammatory cytokines and
chemokines to attract more leukocytes to the area of inflammation. (2) The recruitment of macrophages continues
without healing occurring at the site of injury. (3) As more macrophages are recruited to the area of inflammation,
cytokines and growth factors continue to accumulate in the tissue. (4) Over time, long term resident macrophages
accumulate in the tissue.

Unlike acute inflammation, chronic inflammatory conditions can result in
considerable economic and societal burdens, severely reduced quality of life, and death.
These economic burdens include added overall expenditures in one’s yearly budget and
loss of wages due to complicating factors. The financial burden that is experienced by
patients dealing with chronic inflammatory diseases is considerable for the average
American. Patients that suffer from inflammatory conditions in the United States spend
approximately $38,000 more a year on additional expenditures than healthy individuals.10
This translates to a loss of half of the income in a typical American household,
considering that the median household income from 2015-2019 was $62,843.11 To make
matters worse, those who suffer from chronic inflammatory diseases have a higher
chance of missing work, resulting in lost wages. For example, 24% of the individuals
who suffer from chronic obstructive pulmonary disease (COPD) report being unable to
work, while 5% of patients without COPD report being unable to work.12 Also, rheumatic
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conditions are the leading cause of work disability among adults in the United States.13
Finally, evidence shows that such diseases impact the quality of life; a study examined
the self-reported quality of life of patients with rheumatoid arthritis (RA) and found that
the patients were 30% more likely to need assistance with personal care than people who
did not have RA.14
Although the development of chronic inflammatory diseases involves many risk
factors, evidence suggests cytokine-mediated signaling plays a significant role in
maintaining chronic inflammation. For example, the inhibition of the cytokine tumor
necrosis factor-alpha (TNF-α) has been beneficial for RA patients. A meta-analysis of
data retrieved from PubMed and ISI Web of Knowledge databases revealed eight
randomized control trials (260 participants total) in which anti-TNF-α therapy
significantly reduced insulin resistance in patients with rheumatoid arthritis and improved
their insulin sensitivity.15 This is an important finding, as insulin resistance is associated
with RA.16 Similar effects have been observed with the inhibition of the cytokine
interleukin-1 beta. A double-blind, randomized control trial administering anti-IL-1β
monoclonal antibodies (mAbs) assessed more than 10,000 adults with a previous history
of myocardial infarction events and elevated circulating C-reactive protein levels, which
is a standard biomarker for general inflammation.17 It was found that the administration
of an anti-IL-1β mAb significantly reduced the rates of nonfatal myocardial infarction
and levels of C-reactive protein. Clinical trials such as these suggest that proinflammatory cytokines should be further investigated as biomarkers and therapeutic
targets for chronic inflammatory diseases.
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1.3 Oncostatin M
1.3.1 Interleukin-6 Family of Cytokines
Cytokines are cell-secreted small molecular weight proteins (15-20 kDa) that
work to orchestrate the body’s natural immune response during periods of acute and
chronic inflammation.18 It was not until the 1970s that the Kishimoto group identified the
prototypical glycoprotein 130 (gp130) family cytokine interleukin-6 (IL-6), which is
released by T cells for the purpose of maturation and development of B cells into
antibody-producing plasma cells.19 Therefore, IL-6 was first named B cell stimulatory
factor 2. The biological relevance of IL-6 continued to increase as other factors such as
hepatocyte-stimulating factor and plasmacytoma growth factor were also identified as IL6.20, 21 As time passed, other distinct cytokines were observed to elicit cellular responses
by binding to the gp130 receptor as well. These cytokines were identified throughout the
80’s, 90’s, and 2000’s, and are collectively called the IL-6 family of cytokines.
The IL-6 family of cytokines is comprised of 8 distinct proteins, which include
IL-6, IL-11, IL-27, ciliary neurotrophic factor, leukemia inhibitory factor (LIF),
oncostatin M (OSM), cardiotrophin 1, and cardiotrophin-like cytokine. It should be made
clear that the IL-6 family of cytokines is also referred to as the gp130 family of
cytokines. As they all signal through similar receptor complexes, they share close
structural and behavioral characteristics. This structural similarity is not evident in the
secondary structure of the protein. Still, it is clearly observed in the tertiary structure,
where they all exhibit a four alpha-helical bundle with an up-up-down-down topology.22
Several distinct yet closely related cell signaling pathways can be triggered by the IL-6
family of cytokines, including the Janus kinase-signal transducer and activator of
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transcription (JAK/STAT), the mitogen-activated protein kinase (MAPK), and the
phosphoinositide 3-kinase (PI3K) pathways.23, 24 Therefore, redundancy in signaling
pathways allows some IL-6 family cytokines to elicit similar cell responses.
The human body relies critically on the collection of IL-6 type cytokines to
orchestrate the innate and adaptive immune system necessary for development.25 In
addition to activating B cells into antibody-producing plasma cells, IL-6 also modulates
helper T cell function and survival.26 Helper T cells are known to be “naïve” as soon as
they exit the thymus, and it is not until they encounter antigens presented to them by B
cells that they are activated.27 Interestingly, resting naïve helper T cells undergo apoptosis
soon after isolation. Yet, they have an increased lifetime when stimulated with IL-6.26 In
conclusion, the IL-6 family of cytokines is an important collection of proteins that
regulate several necessary functions within the human body.
1.3.2 Form and Function of OSM and LIF
Both the structure and function of the OSM and LIF cytokines are strikingly
similar, and there is evidence that suggests OSM and LIF share a common evolutionary
origin. Due to the physical closeness of the genes on chromosome 22, it is believed that a
duplication of a common ancestral gene gave rise to the regions on chromosome 22 that
code for OSM and LIF.28 Both OSM and LIF display similarly placed receptor binding
sites, which are illustrated in Figure 1.3. These are commonly referred to as sites II and
III and have been identified by alanine mutagenesis studies to play a significant role in
forming protein-protein interactions (PPIs) between the cytokines and their appropriate
receptors.29-31
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Site II

Site III

LIF

OSM

Ribbon

Figure 1.3

Binding sites of OSM and LIF

The black circles outline the approximate topography that contains site II and site III for both OSM (PDB: 1EVS)
and LIF (PDB: 1EMR). Site III is observed from a top-down view, while site II is observed from a side-view.

In both proteins, site II is dedicated to binding the common gp130 receptor.31
However, LIF and OSM diverge structurally in respect to site III, which dictates their
receptor binding preferences. OSM preferentially forms a signaling complex with gp130
and oncostatin M receptor beta (OSMRβ) to create what is known as the OSMR type II
complex. In addition, OSM can also form a lower affinity signaling complex with gp130
and leukemia inhibitory factor receptor (LIFR) to create what is known as the OSMR
type I complex.31 LIF has only been identified to bind to a signaling complex comprised
of gp130 and LIFR.32 A set of experiments performed by Chollangi and coworkers
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revealed that a helical loop containing 12 amino acids between the B and C helices at site
III of OSM dictates whether OSM preferentially signals through the type I or type II
OSMR complex. The authors used surface plasmon resonance (SPR) binding
experiments to show that when OSM proteins have this helical loop shortened to 7 or 4
amino acids, it dramatically increases their affinity for the type I complex, but not the
type II complex.31 So, this was identified to be an essential structure that is unique to
OSM’s signaling.
Both OSM and LIF are cytokines that exhibit pleiotropic function. In the classic
sense, pleiotropy refers to the effect a single gene, or protein, has on two seemingly
unrelated phenotypic traits. In this context, OSM and LIF are pleiotropic as they mediate
the activity, growth, and differentiation of many different cell types. These effects range
from the bone remodeling process to hematopoiesis and liver development.33 In
comparison, LIF has been identified as the most pleiotropic cytokine in the IL-6 family
and observed to be secreted by a wide variety of cells.32 OSM is primarily secreted by
activated T cells, monocytes, macrophages, polymorphonuclear neutrophils, and dendritic
cells.34
As seen in panel A of Figure 1.4, OSM (yellow) binds to the transmembrane
protein gp130 with relatively low affinity. This binding event alone shows little to no
biological response from the cell.35 It is not until either the transmembrane protein LIFR
or the transmembrane protein OSMRβ is recruited that the JAK/STAT, MAPK/ERK, and
PI3K/AKT pathways are activated by either receptor complex.36 As seen in panel B, LIF
(purple) most likely binds to LIFR first, then to gp130 second to activate the JAK/STAT,
MAPK/ERK, and PI3K/AKT pathways.32, 37

11

Figure 1.4

Signaling pathways of LIF and OSM

(A) OSM (yellow) can form a signaling complex with either gp130 and OSMRβ or gp130 and LIFR to upregulate
the JAK/STAT, MAPK/ERK, and PI3/AKT pathways. (B) LIF (purple) forms a signaling complex with gp130
and LIFR to upregulate the JAK/STAT, MAPK/ERK, and PI3/AKT pathways.

Out of the three pathways, the JAK/STAT signaling cascade is the most
mechanistically straightforward and relevant to this document. Upon cytokine binding to
the receptor subunits, receptor-associated JAK proteins come in close enough proximity
to each other to undergo trans-phosphorylation.38 The phosphorylated JAK proteins then
phosphorylate tyrosine residues on the cytoplasmic tails of transmembrane receptors.
These phosphorylated tyrosine residues act as docking sites for the STAT family of
proteins, whereupon docking they become phosphorylated. Phosphorylated STAT then
dissociates and forms a homodimer or heterodimer STAT complex, which is translocated
into the nucleus to upregulate specific transcripts. The JAK/STAT pathway activated by
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OSM and LIF controls several biological functions, such as the proper regulation of cell
cycle progression and immune system functioning.39-41
1.3.3 Chronic Inflammatory Diseases Maintained by OSM
More evidence is emerging that the overexpression of OSM is implicated in
numerous chronic inflammatory diseases.42-48 As a cytokine that regulates pathways in
multiple tissues, it is inherently challenging to assign all known functions of OSM when
exploring its role in acute and chronic inflammation. Yet, numerous histological
investigations and clinical experiments suggest that OSM plays a pivotal role in chronic
inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease,
metabolic syndrome, systemic sclerosis, lupus, and many different forms of cancer. This
section will serve as a collection of experimental evidence that frames OSM as culpable
in contributing to such illnesses.
1.4 OSM and Breast Cancer
Evidence suggests that overexpression of OSM and OSMRβ can promote the
progression of certain cancers via tumor growth, invasion, and survival.48 Specifically,
OSM has been identified to promote the spread of breast cancer. Breast cancer alone has
accounted for 30% of all cancers in women in the year 2021.49 As such, it is the most
commonly diagnosed type of cancer in women, except for skin cancers. The 5-year
survival rate for women with localized breast cancer is 99%.50 However, the high
mortality rate that is so commonly associated with breast cancer results from the
spreading of cancerous cells to distant sites in the body (metastasis). Once cancer
metastasizes to other vital organs, the five-year survival rate for women drops to a bleak

13
28%. The most common tissues for metastasis to occur in the bones, liver, brain, and
lungs.51
In order to discuss the role of OSM in breast cancer metastasis, it is necessary to
identify the tissues in which breast cancer originates. Breast carcinomas are generally
classified as lobular or ductal. Of all newly diagnosed breast cancers, 15-30% are
identified as being in situ carcinomas; 80% of these carcinomas are identified as ductal
carcinoma in situ, in which the carcinoma originates inside the milk ducts of the breast.52,
53

Breast cancer types can be further categorized into four major subtypes, which include

luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and
triple negative breast cancer (TNBC).54 All four of these sub-types of breast cancer
depend on the expression of estrogen receptor (ER), progesterone receptor (PR), and
HER2. Table 1.1 summarizes which types of breast cancers express certain receptors.55
Table 1.1

Receptors present in breast cancer subtypes

Luminal A and luminal B cells both express PR and ER, but luminal A cells do not express HER2. HER2-enriched
cells express HER2 but do not express PR or ER. TNBC does not express any of the receptors discussed.

Luminal A Luminal B HER2-enriched TNBC
PR/ER
+
+
HER2
+
+
Breast cancer cells have the potential to become metastatic. Metastasis occurs
when a cancer cell breaks away from the primary tumor site, enters the bloodstream or
lymphatic system, and continues to grow and divide in distant tissue(s).56 The metastatic
cascade is initiated when the tumor cells experience a phenotypic change, called an
epithelial to mesenchymal transition. This specific change causes the epithelial cell to be
able to detach from the basement membrane and assume a mesenchymal cell phenotype,
which includes enhanced migratory capacity and invasiveness. Afterward, the cancer cell
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enters the circulatory or lymphatic system through a process called intravasation, where
the cancer cell then becomes a circulating tumor cell. Finally, extravasation occurs when
the circulating tumor cell travels to a distant tissue site, whereupon it exits the circulatory
or lymphatic system into adjacent tissue and creates a new tumor.57
OSM has been implicated in upregulating several mechanisms that support cancer
growth, metastasis, and survival.48 Jorcyk and coworkers have shown that OSM increases
the metastatic capacity of T-47D breast cancer cells.42 To determine how OSM affects the
detachments of cells, the researchers incubated cancer cells with 3H-thymidine to
radiolabel the DNA to quantify the degree of cellular detachment. Next, the cells were
incubated with three different cytokines: OSM, IL-6, and LIF. The percentages of
detached cells were quantified as loose cells in the culture media divided by the total
number of cells. It was found that OSM induced a detachment of 17%, while untreated
cells induced a detachment of 6%. In addition, the introduction of IL-6 induced an 8%
detachment, while LIF was observed to have no effect.
In addition, Jorcyk and coworkers showed that OSM significantly increased the
invasive capacity of T-47D cells.42 T-47D cells were treated with OSM and plated in
Matrigel-coated invasion chambers for 3 or 5 days. After the allotted time, the invasive
cells were stained and counted. It was found that OSM-treated cells showed a 250%
increase in invasive capacity compared to untreated cells. Overall, the data suggest that
OSM induces an epithelial to mesenchymal transition by the cell detachment assay and
significantly increases cancer cell invasiveness.
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1.5 OSM and Rheumatoid Arthritis
In addition to increasing metastasis in breast cancers, OSM has also been
implicated in the pathogenesis of inflammatory joint diseases, such as rheumatoid
arthritis (RA). RA is an autoimmune disease typically associated with autoantibodies,
matrix metalloproteinases (MMPs), overactivation of osteoclasts, and joint swelling.58
Not only is the QOL of an RA patient diminished, but the life expectancy is slightly
shorter due to accelerated arteriosclerosis.59 RA is not strictly attributable to genetic
factors as environmental factors play a role as well. Such factors include inhalation of
dangerous debris particles (such as silica and asbestos), tobacco/alcohol consumption,
microbiota, diet, and other lifestyle stressors.60 Like other chronic inflammatory diseases,
RA can either be diagnosed as early-stage or late-stage. However, it is common for RA to
be undiagnosed until the later stages, after which medical intervention would most
effectively benefit patient prognosis.61
Even though RA is considered a systemic disease, the chronic inflammation of
RA takes place in the synovial tissue of the joint (synovium). The two sections that
constitute the synovium are the intimal and the subintimal layers.62 The intimal layer is
the innermost layer in the joint capsule and serves two purposes. The first purpose is to
secrete synovial fluid into the joint space, thereby lubricating and decreasing the friction
between the cartilaginous structures. The second purpose is to supply nutrients to the
cartilage contained within the joint capsule.63 Although both discrete layers of the
synovium experience physiological changes in response to RA, the intimal layer
experiences the most pronounced changes.
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A normal, healthy, intimal lining of the synovium is 1-2 cells in depth. However,
the influx of both macrophage-like synovial cells and fibroblast-like synoviocytes (FLS)
causes the intimal lining to expand to 10-20 cells in depth.58 As seen in step 1 of Figure
1.5, the macrophage-like synovial cells migrate into the synovial tissue. In step 2, the
macrophages become activated by infiltrating T cells, whereupon they secrete
cytokines.58, 64 In step 3, FLS are then activated by the secreted cytokines to produce the
devastating matrix-metalloproteases (MMPs) and receptor activator of nuclear factor
kappa beta (RANK) ligand. MMPs facilitate cartilage destruction, while RANK ligand
upregulates the proliferation and activity of osteoclasts.65, 66 Finally, step 4 shows an
increased number of osteoclasts in the joint, as well as degradation of cartilaginous
structures in the joint by MMPs.67

Figure 1.5

Cytokines work to maintain joint destruction in RA

(1) Leukocytes are attracted to the area in response to the autoimmune reaction in RA,. (2) T cells activate
macrophages, which results in the secretion of pro-inflammatory cytokines, such as IL-1, IL-6, TNF-alpha, and
OSM. (3) The cytokines activate fibroblast like synoviocytes to release RANK ligand and MMPs. (4) MMPs
destroy cartilage and osteoclasts are activated by RANK ligand, resulting in articular cartilage and bone loss.

Research executed by Fearon and coworkers reveals how OSM causes a proinflammatory phenotype in FLS, which are identified in the paper as rheumatoid arthritis
fibroblasts.44 In one of the experiments, the authors sought to discover what effect OSM
had on the proliferation of the FLS. The FLS were stimulated with OSM for 96 hours, at
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which time the cells were lysed and levels of bromodeoxyuridine were quantified via an
enzyme-linked immunosorbent assay (ELISA). The cells that were stimulated with OSM
resulted in cell proliferation that was approximately twice that of the control group. This
supports the position that OSM is involved in the pannus structure's growth- a prominent
pathological feature observed in progressed RA. The pannus grows and spreads in a
locally invasive tumor-like fashion and is comprised of osteoclasts, macrophages, and
invasive fibroblast-like synoviocytes.58 Once the pannus envelops cartilage and
underlying bone it will start to degrade them.
Another key finding in the set of experiments performed by Fearon and coworkers
suggests that OSM induces the expression of matrix metalloproteinase-1 (MMP-1),
which catabolizes cartilaginous tissue. The authors harvested tissue explants from RA
patients to maintain the synovial tissue architecture during the experiment. The explants
were stimulated by OSM for 24 hours, lysed, and subjected to promatrix
metalloproteinase-1 (proMMP-1) detection by ELISA. ProMMP-1 is simply a proenzyme
that upon activation becomes MMP-1.68 The researchers found that proMMP-1
production in the OSM stimulated explant increased by 154% when compared to the
control explant. These data support the idea that OSM can maintain joint destruction by
stimulating the production of MMP-1.
Hui and coworkers revealed that OSM is found in elevated amounts in the
synovial fluid of patients with RA.69 In the experiment, cells from synovial fluids were
collected from patients with RA or patients with osteoarthritis and subjected to an OSM
ELISA. The authors discovered that 90% of the patients with RA had synovial fluid OSM
concentrations of 2.36 to 901.75 pg/mL, while there was no detectable OSM in the
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synovial fluid of patients with osteoarthritis. It is worth noting that the limit of detection
for the ELISA experiments was 2.0 pg/mL for RA synovial fluid and 4.0 pg/mL for
osteoarthritis synovial fluid. In combination with the experiments performed by Fearon
and coworkers, these findings suggest that OSM promotes tissue inflammation in RA
patients and upregulates pathways that destroy cartilaginous and bony structures.
1.6 OSM and Irritable Bowel Disease
Irritable bowel disease (IBD) is another condition in which overexpression of
OSM is thought to contribute to disease severity. IBD poses an important significance in
Western world health, as gastrointestinal disorders are among the most frequent causes
for medical health consultations.70 In fact, IBD has become a major focus worldwide as
the incidence and prevalence have been increasing in developed countries around the
globe.71 IBD is clinically identified as one of two sub-types: Ulcerative Colitis (UC) or
Crohn’s Disease (CD).72 Currently, there are no non-invasive cures for CD and UC,
resulting in individuals who have a considerable likelihood of needing surgery. For
individuals with CD, the likelihood of requiring surgery in one’s lifetime is 70-80%,
while the likelihood of requiring surgery for UC is 20-30%.73
Unfortunately, no single symptom or reference allows a clinician to positively
diagnose a patient with CD or UC. Instead, a combination of clinical and histological
evidence needs to be gathered according to the European Crohn’s and Colitis
Organization Guideline for Diagnostic Assessment in Inflammatory Bowel Disease. The
diagnosis of both UC and CD is “…based on a combination of clinical, biochemical,
stool, endoscopic, cross-sectional imaging, and histological investigations.”74 Despite the
uncertainty of disease etiology, recent evidence identifies cytokines as key players in
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driving intestinal inflammation. According to Sanchez-Muñoz and coworkers, IBD
pathogenesis is influenced by cytokine-induced dysregulation of T cells and excessive
production of effector T-cells.75
Currently, Food and Drug Administration-approved TNF-α monoclonal
antibodies (infliximab) are used to treat moderate to severe UC and CD with marked
success. Still, an astounding 40% of the patients experience non-responsiveness to the
treatment. To make matters worse, patients can become unresponsive to anti-TNF-α mAb
therapy over time.76, 77 These conditions are commonly referred to as a lack of primary
response and a loss of response, respectively. The lack of patient response to anti-TNF-α
therapies may be due to other cytokines causing inflammation.
More evidence is emerging in the primary literature revealing OSM's role in the
pathogenesis of IBD. West and coworkers identified OSM as the most transcriptionally
upregulated cytokine in inflamed intestinal mucosa in patients with CD and UC.43
Additionally, OSMRβ was observed to be upregulated in both CD and UC patients,
which suggests a specific role for OSM and OSMRβ in the pathogenesis of IBD.
Interestingly, the authors also found that OSM and OSMRβ expression is positively
correlated with the severity of intestinal inflammation. Although the authors do not
suggest a discrete pathway in which OSM acts to drive IBD, they did show that OSM
promotes inflammatory activity in the intestinal stroma.
West and coworkers treated CCD-18Co (human colon) cells with recombinant
OSM and used reverse transcription-quantitative polymerase chain reaction to quantify
the expression of OSM-associated inflammatory module genes.43 This was done to
observe OSM’s potential role in inducing a pro-inflammatory phenotype among the colon
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cells. The authors found that half of the module members were induced by OSM
stimulation. Also, the addition of OSM induced the expression of both intercellular
adhesion molecule 1 (ICAM1) and podoplanin. This is important, as ICAM1 plays a role
in facilitating leukocyte endothelial transmigration.78 This translates into more leukocytes
infiltrating the affected area, which further increases inflammation. In addition, ICAM1 is
believed to contribute to further gut permeability by disruption of the endothelial cell
junction.79 The upregulation of podoplanin should be noted as well, as it has been
identified to play a role in other chronic inflammatory diseases such as psoriasis, multiple
sclerosis, and cancer-associated thrombosis.80 These data suggest that OSM upregulates
migration and invasion-leading of leukocytes, as well as increases gut permeability.
West and coworkers also used an IBD model driven by Helicobacter hepaticus to
infect wild type (WT) C57BL/6 mice to mimic human IBD conditions.43 For context,
Helicobacter hepaticus is a type of bacteria that has been used to induce colitis in mice.81
Three separate experiments were performed using this model to observe what role OSM
has in contributing to IBD pathogenesis. In the first experiment, mice were infected with
Helicobacter hepaticus to validate the model. The mice were sacrificed after 14 or 21
days, corresponding to peak disease severity. The mice were observed to have a 10-fold
increase in leukocytes of the colon lamina propria, along with elevated levels of OSM in
colon explant supernatants and stool samples. High levels of expression of both OSM and
OSMRβ were detected in the lamina propria as well. In addition, the lamina propria was
highly enriched in PDPN cells. This evidence suggests that both OSM and OSMRβ are
associated with colitis in this specific model.
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In the second experiment, West and coworkers used OSM deficient mice along
with co-housed WT mice to observe how the lack of expression of OSM influenced
disease progression. At a steady-state of IBD severity, the OSM deficient mice exhibited
a normal collection of leukocytes in the lymphoid and intestinal tissue. Also, the OSM
deficient mice exhibited normal organ histology. During peak IBD severity, the OSM
deficient mice showed less severe symptoms in comparison to their WT littermates.
Genomic DNA of Helicobacter hepaticus was quantified using quantitative polymerase
chain reaction (qPCR) to reveal that bacterial colonization of both mouse groups was the
same. This confirms that any changes observed in the experimental groups were not
attributable to any possible differences in Helicobacter hepaticus colonization. The
results from this experiment suggest that OSM dramatically contributes to the severity of
IBS.
In the third experiment, West and coworkers treated the infected mice with an
OSMRβ-gp130 fusion protein to neutralize OSM. Fusion proteins are two or more
domains that have been joined together to transcribe a single polypeptide. This results in
two separate proteins linked together that normally would not be. Therefore, the OSMRβgp130 fusion protein mimics the OMSR type II receptor complex.82 The mice treated
with the higher affinity OSMRβ-gp130 fusion protein exhibited similar levels of disease
severity as that of OSM deficient mice. These experiments collectively suggest that not
only does OSM likely play a role in IBD pathology, but it also identifies OSM as a
therapeutic target for patients who do not respond to anti-TNF-α therapy.
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1.7 OSM and Systemic Sclerosis
Finally, OSM has been shown to play a role in the chronic autoimmune disease
systemic sclerosis (SSc). Clinical features of the disease include fibrosis, vascular
damage, and disruption of innate and adaptive immunity. The most prominent feature of
the disease is the progressive fibrosis that occurs in different organs due to excessive
deposition of extracellular matrix components.83 SSc is typically classified into two
subsets based on the regions of affected skin. These two subsets include limited systemic
sclerosis (lcSSc) and diffuse systemic sclerosis (dsSSc). LcSSc is defined as sclerosis that
affects the face and limbs, whereas dsSSc is defined as sclerosis that affects the axial
parts of the body, such as the trunk and proximal portions of the limbs.84, 85 Once
diagnosed, the ten-year survival rate for lcSSc patients is 90%, while the ten-year
survival rate for dsSSc is 65-82%. Unfortunately, the pathogenesis of both types of
sclerosis is still under heavy scrutiny.
However, a set of studies executed by Marden and coworkers examined the
possible contribution of the OSM/OSMRβ signaling axis to the development and
maintenance of SSc.46 The authors obtained skin biopsies from human subjects that were
healthy or affected with either lcSSc or dsSSc. From the biopsies, human dermal
microvascular endothelial cells (HDMECs) were isolated and cultured. Both cells and
biopsy tissues were subjected to experiments that quantified the expression of OSM and
OSMRβ, mRNA levels of pro-inflammatory genes, and specific cells implicated in the
pathogenesis of SSc.
Immunohistochemical staining experiments on the tissue biopsies revealed that
both lcSSC and dsSSc tissues had elevated levels of OSMRβ. Surprisingly, the
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expression of OSM in both SSc biopsies was comparable to that of the healthy control
group. The results from the staining experiment alone reveal that OSM is not expressed
in higher amounts than that of healthy patients; however, they do show that OSMRβ is
expressed in higher amounts in patients that have either form of SSc. This is important as
OSMRβ has been identified as a biomarker for the progression of skin disease in dsSSc
patients.86
In addition, the authors used real-time PCR to quantify mRNA levels of specific
interleukins, chemokines, and cell permeability and adhesion molecules in HDMECs
treated with OSM for three and twenty-four-hour time periods. A rapid increase in IL-6
mRNA was observed in the cells treated with OSM during the three-hour mark and
remained elevated at the twenty-four-hour mark. Interestingly mRNA levels of OSM
were the same as the control group. The only other IL-6 family cytokine that was
monitored to increase was IL-33 along with its receptor IL-1R1. The mRNA levels of the
chemokines CCL7, CXCL12, and CXCL2 were also observed to be significantly higher
than that of the control group at the three-hour and twenty-four-hour time periods. The
mRNA levels of ICAM-1 were also found to be upregulated as well. These data suggest
that OSM upregulates mRNA levels of other inflammatory cytokines, chemokines, and
adhesion molecules, therefore driving inflammation.
Finally, Marden and coworkers explored how OSM possibly mediates collagen
deposition in healthy human explant tissues, as collagen deposition correlates with
disease activity in SSC.46, 87 This was accomplished by placing the dermal biopsy tissues
on nitrocellulose membranes, treating them with OSM for fourteen days, and staining
them on paraffin sections. The OSM-treated explants experienced increased collagen

24
deposition and an increased number of platelet-derived growth factor receptor beta cells,
expressed in the dermal tissue of patients with early SSC.88 These data show that OSM
can increase the common mechanisms in SSc associated with disease severity, such as the
deposition of collagen and the expression of pro-inflammatory platelet-derived growth
factor receptor beta cells.
Collectively, the data obtained by Marden and coworkers show that OSM
upregulates several mechanisms involved in the pathogenesis of SSc. This is supported
by the increased expression of OSMRβ in OSM-treated tissue explants. Furthermore,
mRNA levels of IL-33, several chemokines, and ICAM-1 were observed to be
transcriptionally upregulated in HDMECs treated with OSM. Lastly, the treatment of
healthy patient dermal explants showed OSM increases collagen deposition. These sets of
experiments highlight OSM as a potential therapeutic target in treating both dsSSc and
lcSSc.
1.8 Disruption of Protein-Protein Interactions
1.8.1 Introduction to Protein-Protein Interactions
The Human Interactome Project is a growing collection of protein-protein
interactions (PPIs). Analogous to the Human Genome Project that had its inception in
1990, the Human Interactome Project works to understand and map out the expansive
collection of PPIs in the context of human biological systems. Specific requirements need
to be met for an interaction to be qualified as a PPI. An association between two proteins
is only considered to be a canonical PPI if it meets the following two requirements:
Firstly, the interaction between the two proteins has to result in a specific event, and
secondly, the interaction must activate a non-generic function.89 This distinction is
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necessary, as the mere “touching” of proteins (such as those experienced in the
production, folding, and transport of proteins) are not deemed as PPIs.
1.8.2 Recent Challenges and Successes in Targeting PPIs
It has become more evident that the etiologies of certain diseases arise from
dysregulated mechanisms controlled by PPIs. According to Heifetz and coworkers,
“There are more than 645,000 reported disease-relevant PPIs in the human
interactome…”90 Modulation of such interactions could prove to be highly promising
therapeutic approaches. This sub-chapter will discuss the inherent challenges associated
with inhibiting PPIs, and the recent successes researchers and clinicians have had.
Despite modern success in small molecule protein-protein interaction inhibitors
and their practical applications, inherent challenges make designing potent, selective, and
safe compounds difficult. The limitations arise from the shallow binding “pockets” and
the relatively flat, featureless surface areas of proteins. In addition, the sheer difference in
the size of the protein-protein interface versus the small molecule-protein interface also
makes the inhibition challenging. As the Human Interactome Project contains entities of
various sizes and structures, the interfacial buried surface area of the PPI can vary widely.
In other words, buried surface area at the protein-protein interface has been measured to
span the range of < 1000 Å2 to > 2500 Å2.91 In comparison, typical small moleculeprotein interfaces constitute a total buried surface area of ~200-1000 Å2.92 Also, the
rational design of lead molecules is daunting as well; there are very few naturally
occurring small molecules that mimic the complementary binding partner of the target.
One advancement that has progressed drug discovery is alanine scanning, which
identifies important amino acids in binding epitopes on proteins. Essentially, alanine
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scanning works by replacing individual amino acids at the putative binding epitope of the
protein with a single alanine residue. Alanine is chosen because of its non-bulky,
chemically inert character. Afterward, the biological activity of the mutant protein is
measured. Cunningham and Wells were the first to use alanine scanning experiments to
find “hot spots” to map human growth hormone-receptor interactions.93 Hot spots are
small regions of amino acids in which most of the energy of binding is concentrated.
Having no real practical starting point, the authors systematically replaced 7 to 30 residue
segments with sequences derived from non-binding hGH (human growth hormone)
homologs. As a result, the NH2-terminal portion of helix 1, the COOH-terminal portion
of helix 4, and a loop structure that resides between residues 54 and 74 were discovered
to be potentially critical in hGH receptor binding. The authors then performed another
round of alanine scanning experiments to identify which specific side chains in hGH
were most important in receptor binding. A total of 62 single alanine mutant proteins
were designed and secreted from Escherichia coli, and binding constants were measured
and recorded for each mutant.
From the mutagenesis experiments, Cunningham and Wells identified certain
regions of amino acids that, when mutated, caused a significant decrease in the binding
ability of the proteins.93 These amino acid residues are confined to three and one-half
turns of helix 4. The authors also showed that only a small percentage of the buried side
chains in the protein account for a drastic contribution to the binding energy of the entire
hGH protein to its receptor. To be more specific, only 8 of the 31 side-chains buried at
the PPI accounted for approximately 85% of the binding energy.94 This finding is
significant in the context of inhibiting PPIs with small molecules, as it suggests that small
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groups of amino acids can be targeted with a small molecule or biologic that does not
necessarily have to mimic the surface area of the complementary receptor protein.
Further discussion in this section will cover examples of various protein-protein
inhibitors such as monoclonal antibodies and peptide-mimetic small molecule inhibitors.
Monoclonal antibodies (mAbs) deserve due attention as they account for almost a
fifth of the Food and Drug Administration's new drug approvals each year.95 Monoclonal
antibodies are immunoglobulins designed to target a single specific antigen. The process
of manufacturing mAbs is initiated by injecting mice, rats, or hamsters intraperitoneally
with the target antigen. This stimulates the B cells in the spleen to produce antibodies
specific to the target antigen injected. Next, the B cells in the spleen of the rodent are
harvested and fused with myeloma cells to create the hybridoma cells, which then can
divide to produce more antibodies. Once the hybridoma cells have produced enough
mAbs, the mAbs are filtered out and purified for further use.96 Such applications include
diagnostic testing in consumer items such as at-home pregnancy tests or clinical
applications, such as treating cancer in human patients.97, 98 In addition, mAbs have also
been used to target PPIs.
One such example of a mAb designed to disrupt a PPI is Daclizumab®, used for
treating relapsing forms of multiple sclerosis. Daclizumab is a humanized monoclonal
antibody developed by Biogen and AbbVie that blocks CD25, the α-subunit of the
Interleukin-2 receptor of effector T-cells.99 It is currently believed that Daclizumab binds
reversibly to the subunit receptor CD25, which decreases the consumption of IL-2 by the
high-affinity receptor. As a result, the intermediate affinity IL-2 receptor is preferentially
activated and induces an IL-2 driven expansion of CD56bright natural killer cells. The
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increase in CD56bright natural killer cells has a significant role in the effectiveness of the
mAbs, as the natural killer cells are believed to be cytotoxic to auto-antigen activated T
cells.100-102 Since auto-antigen T cells target the host's body in multiple sclerosis,
reducing these cells helps alleviate the adverse effects of the disease.103
Another method of inhibiting PPIs includes the use of peptide-based protein
mimetics. This type of approach has the advantage of mimicking structures and motifs
present in the binding partner(s) of the protein. However, the drugs' poor solubility and
metabolic instability have been a serious limitation to their uses in clinical
applications.104 Despite these issues, there have been several unique attempts to
circumvent them. Such approaches include using macrocycles, constructing shorter
peptides, introducing non-natural amino acids and conformationally restricted cyclized
peptides.104 More recently, mimetic applications of protein-protein inhibitors have shown
great promise and have considerable room for growth and improvement. A few of these
successful protein mimetic small molecule inhibitors (SMIs), along with their design
rationale, will be discussed.
Venetoclax was designed to treat acute myeloid leukemia (AML). AML is
characterized by the rapid generation of myeloid progenitor cells and abnormal
differentiation of the myeloid cells.105 In healthy subjects, these myeloid progenitor cells
differentiate into red blood cells, platelets, and different types of leukocytes.106 In patients
suffering from AML, these myeloid cells differentiate into malignant blood cells,
resulting in a loss of function for proper hematopoiesis (production of blood cells). The
mainstay treatment for AML includes one, two, or all three of the following approaches:
chemotherapy, stem cell transplant, and small molecule therapy.107 The small molecule
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therapies used to help treat AML are designed to reinstate normal apoptosis within the
myeloid cells that are rapidly proliferating, thereby treating a component of the disease.
The BCL-2 family of proteins regulates both pro-apoptosis and anti-apoptosis
mechanisms.108 Venetoclax was designed to bind to BCL-2 and inhibit the interaction
between the two proteins B cell lymphoma-2 (BCL-2) and BCL-2 associated X-protein
(BAX), which play a role in regulating apoptosis. Unbound BAX acts as a pro-apoptotic
protein but is inhibited when bound to the protein BCL-2. Therefore, Venetoclax binding
to BCL-2 results in more unbound BAX that is available to initiate apoptosis in myeloid
progenitor cells.
Panel A of Figure 1.6 shows Venetoclax bound to the hydrophobic groove on
BCL-2 (PDB ID: 6O0K), which consists of binding sites 1 and 2, as identified by
Oltersdorf and coworkers.109 To design a rational drug, researchers at Abbott
pharmaceuticals targeted the hydrophobic groove of the BCL-2 protein by a method
known as “SAR by NMR,” which is accomplished by obtaining HSQC spectra of 15Nlabeled protein in the absence and presence of possible binding fragments.110
Specifically, the Abbott researchers screened the fragments contained in the H3 portion
of the BAX protein, which has been identified as the portion of the alpha-helix that binds
to BCL-2. The fragments that were identified to bind with the greatest affinity were
joined together to produce early versions of Venetoclax. Eventually, the final structure of
Navitoclax (Ki < 1 nM) was synthesized, as seen in panel B of Figure 1.6.
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Figure 1.6

Venetoclax targets site 1 and site 2 of BCL-2

(A) Two similar binding poses of Venetoclax to the BCL-2 protein are shown. The crystal structure of Venetoclax
bound and BCL-2 reveals that the compound binds to site 1 and site 2 of the BCL-protein. (B) Venetoclax mimics
the structure of the BAX protein binding epitope and has a Ki < 1nM.

Lee and Coworkers have also developed a protein mimetic as a potential
therapeutic for Alzheimer’s disease.111 These α-helix mimetics were designed to disrupt
the p53-MDMX interaction stabilized by three residues (Phe19, Trp23, and Leu26) of
p53 and by the hydrophobic pocket of MDMX. As seen in panel A of Figure 1.7, short
helical peptides seem to play an essential role as a recognition motif, where side chains
exist at the positions: i, i+3 or i+4, and i+7. Therefore, the researchers designed a
pyrrolopyrimidine-based scaffold with variable R groups that mimicked the spacing seen
in the short helical peptide configuration (panel B). The authors then created a 900member library of compounds that were substituted at the R1, R2, and R3 positions. In
order to study the compounds' abilities to disrupt the p53-MDMX interface, the
molecules were tested to see how efficiently they could displace a Rhodamine-labeled
15-mer p53 peptide from the MDMX protein using a fluorescence polarization assay.
This assay revealed that two analogs, 3a and 3b, had Ki values of 0.62 ± 0.12 μM and
0.45 ± 0.18 μM, respectively.
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Figure 1.7

Small molecule α-helix mimetic

(A) Side chains at i, i+3 or i+4, and i+7 positions of the helix play an important role in disrupting PPIs. (B) The
pyrrolopyrimidine-based scaffold mimics the placement of R groups at the i, i+3 or i+4, and i+7 position.

Ran and coworkers designed and screened peptide-based inhibitors of heat shock
factor 1 (HSF1).112 HSF1 is studied as a biomarker and promising therapeutic target as it
is implicated in the migration, invasion, and proliferation of cancer.113 HSF1 is a
transcription factor that regulates the expression of chaperones and other factors involved
in cell survival during periods of stress. Crystal structures suggest that the HSF1
oligomers are held together by buried contact surfaces, making the monomers
challenging targets. However, the authors used what is referred to as the leucine zipper 4
and oligomerization domain motifs as templates to design peptide mimetics.
To design inhibitors for HSF1, the authors identified which regions of the
oligomerization domain and leucine zipper 4 portions contributed to stabilizing the
binding event. Next, they designed and synthesized peptides that mimicked discrete
stretches of the peptide sequence of both regions. The peptide mimetics of the
oligomerization region were found to be poor inhibitors, while the peptide mimetics of
the leucine zipper 4 region were found to display moderate affinity to the target via a
plate fluorescence assay (EC50 ~ 13 μM). The findings support the notion that even
deeply buried binding regions of proteins can be targeted.
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One of the earliest clinically approved examples of an SMI is Tirofiban
(Aggrastat®). First approved for patient use in 1998, the drug was designed to keep
platelets in the bloodstream from coagulating, which leads to lower chances of blood
clots and heart attacks.114 To decrease aggregation of platelets, Tirofiban inhibits the PPI
between fibrinogen and the platelet integrin receptor glycoprotein llb/lllα. The drug itself
is a mimetic of the Arg-Gly-Asp peptide epitope of fibrinogen. In order to produce the
first generation of the drug, the authors performed a directed search of the Merck Sample
Collection, which allowed them to generate a specific structure using defined distances
and atom requirements. The first compound synthesized was named “Lead Compound
1,” as seen in panel A of Figure 1.8.

Figure 1.8

Structure of Lead Compound 1 and Tirofiban

(A) Lead Compound 1 was designed using the Merck Sample Collection. (B) Optimization at both termini of the
original lead compound 1 lead to the final construction of Tirofiban, a Food and Drug Administration approved
SMPPII.

Lead Compound 1 was subjected to a platelet aggregation assay that monitored
the change in light transmittance upon the aggregation. The IC50 was defined as the
concentration necessary to inhibit the change in light transmittance by 50%.115 This assay
revealed that Lead Compound 1 exhibited an IC50 of 27 µM, which served as a good
starting point. However, further structural changes needed to be made to increase the
affinity of the SMI to the substrate. It was discovered that a 4-(4-piperidinyl)butyl linkage
at the N terminus of the structure allowed for the deletion of a chiral carbon seen in Lead
Compound 1. It was also found that the replacement of the benzyl carbamate group at the
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C-terminus with the (S)-butylsulfonylamino group led to increased potency, as well as
more favorable physiochemical properties. Interestingly, the dramatic increase in potency
with the introduction (S)-butylsulfonylamino was not planned and seemed to be a
serendipitous discovery. Together, these changes afforded the final compound Tirofiban,
which has an IC50 of 9 nM (panel B).115
1.8.3 OSM as a Therapeutic Target
Considering OSM has been shown to play a critical role in the maintenance of
several chronic inflammatory diseases, it is an obvious therapeutic target. Clinical trials
using an anti-OSM monoclonal antibody suggest that OSM can be targeted safely, with
minimal side effects.116, 117 The monoclonal antibody GSK2330811, developed to treat
fibrotic and inflammatory diseases, is thought to act by binding to OSM, which prevents
ligating the gp130 receptor.116 GSK2330811 was the first mAb to show target
engagement in skin and blood in human patients. In addition, it became the successor
mAb to GSK315234, which was discontinued due to a lack of binding affinity towards
OSM. In this trial, thirty test subjects were randomized to receive the anti-OSM mAb,
and ten received a placebo. Overall, none of the patients experienced any adverse side
effects that led to withdrawal from the trial. However, there was an observed dosedependent reduction in hematocrit, hemoglobin, and platelet count. Therefore, it is
conceivable that OSM can be safely targeted with no to minimal side effects.
Previously discussed in the work of West and coworkers, fusion proteins have
also been used to inhibit OSM signaling in a murine model of IBD.43 The authors
compared the inhibitory potency of the fusion protein to commercially available antiOSM polyclonal antibodies, and they found that their most potent fusion protein was 50-
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100x more potent than the commercially available polyclonal antibodies. However,
fusion proteins that target OSM have not been used in any clinical trials yet.
1.8.4 Targeting the OSM/OSMRβ receptor complex with SMIs
To the best of the knowledge of the Warner research group, there are no small
molecules that have been published that directly bind to the active site of OSM, thereby
inhibiting the JACK/STAT signaling cascade activated by OSM. A substantial amount of
work has been accomplished to identify the hot spot on OSM responsible for forming the
type II signaling complex.29, 30, 118 As seen in Figure 1.9, OSM works to upregulate
inflammatory gene transcription by a series of phosphorylation steps involving the JAK
and STAT3 proteins. However, an SMI that binds to site III with significant affinity can
render OSM unable to upregulate inflammatory gene transcription. Therefore, the key
signaling pathway that is culpable of maintaining multiple chronic inflammatory diseases
is downregulated.
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Figure 1.9

Inhibition of OSM signaling using an SMI

(A) Upon binding with the transmembrane receptors gp130 and OSMR, the OSM protein induces a
phosphorylation cascade which results in the dimerization of STAT3 proteins. The STAT3 dimers then get
translocated into the nucleus of the cell, where it upregulates inflammatory gene transcription. (B) OSM is
inhibited by an SMI bound to site III of the protein. As a result, the STAT3 proteins will not dimerize and enter the
nucleus. Therefore, no inflammatory gene transcription will be upregulated.

Despite the recent success that monoclonal antibodies have achieved in treating cancers
and chronic inflammatory diseases, clinical applications have significant drawbacks. The
major challenge that accompanies mAbs therapy is the cost to the patient. The average
price of a mAb was $96,731/year (through the years 1997-2016), while the annual cost of
small molecules was $730/year in 2013.119, 120 Oral SMIs are favorable due to their
shorter half-life in the body compared to mAbs, which have half-lives between 11-30
days.121 The long clearance time and half-life of mAbs pose a serious issue if there is a
case in which the patient has a severe reaction to the drug or biologic. In contrast, small
molecule drugs typically have half-lives on the scale from hours to days.122-124 Finally,
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the size of mAbs limits their ability to penetrate the CNS. This can be an issue if the
therapeutic targets have infiltrated CNS tissues.125
1.9 Summary of Chapter One
This chapter contained a brief discussion of chronic inflammation and how it
burdens societies and economies worldwide. In addition, specific pro-inflammatory roles
of OSM were identified in breast cancer, rheumatoid arthritis, irritable bowel disease, and
systemic sclerosis. Several works were discussed in which small molecule inhibitors were
rationally designed to treat different types of cancers, heart attacks, and strokes. Finally,
OSM was discussed as a realistic therapeutic target; mAbs have shown that targeting
OSM itself does not result in any serious health concerns. The next chapter will discuss
how specific OSM amino acids were identified as critical in OSMR type II complex
binding. The synthesis and the design of the small molecules targeting OSM will be
presented as well.
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CHAPTER TWO: DESIGN AND SYNTHESIS OF SMALL MOLECULES
2.1 Overview of Chapter Two
As described in chapter 1, there is a considerable amount of evidence that frames
OSM as a potential therapeutic target for the treatment of several chronic inflammatory
diseases. This highlights a need for affordable small molecule drugs that target OSM and
inhibit its pro-inflammatory signaling pathway. The first logical step in designing a small
molecule inhibitor for any protein is to understand the landscape of the protein and
identify the amino acids that are important for receptor activation. Once a druggable site
on the protein is successfully identified, a small molecule inhibitor can be designed.
Seminal work for the OSM-SMI project has already been accomplished by a
multidisciplinary, collaborative research group consisting of Dr. Don Warner, Dr. Cheryl
Jorcyk, Dr. Lisa Warner, Dr. Matt King, and Dr. Danny Xu (Idaho State University).
Potential binding sites of OSM were independently identified and were consistent with
the three binding sites reported in the literature. These include sites I, II, III. Using a
high-throughput virtual screening targeting site III of OSM, 26 structures were identified
as potential lead compounds. The most promising lead compounds were identified to be
SMI-8, SMI-10, and SMI-26. The design and synthesis of SMI-8 analogs are described
herein.
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2.2 Elucidation of OSM Binding Sites
2.2.1 Surface Analysis of OSM Identifies Favorable Binding Sites
Potential ligand binding sites on OSM were predicted by collaborator and
computational chemist Dr. Danny Xu using the AutoLigand program.1 The program was
used to scan the surface of the human OSM crystal structure (PDB ID: 1EVS) for
potential ligand-binding sites. As seen in panel A of Figure 2.1, three potential sites were
identified with favorable energy/volume ratios. As seen in panel B, site III was
determined to contain the highest energy of binding while having the smallest volume in
the binding pocket (E/V = -2.45). Therefore, site III was identified to be the preferred
region of OSM to target with an SMI. It should be noted that the binding sites predicted
by Dr. Danny Xu agree with literature that identifies sites I, II, and III as receptor-binding
sites.2-4

Figure 2.1

Predicted binding sites of OSM

(A) Computational modeling of OSM revealed three potential ligand binding sites.
(B) Site III was calculated to have the highest energy to volume ratio (-2.45 E/V).
The data were obtained by Dr. Danny Xu. Image courtesy of Dr. King.
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2.2.2 In Vitro Alanine Scanning Experiments of OSM
Deller and coworkers obtained the first crystal structure of OSM and performed
the first set of alanine scanning experiments of the protein in 2000.3 The crystal structure
was obtained first, which allowed the authors to identify amino acid stretches likely to
participate in OSMRβ binding. After being identified, these specific stretches were
subjected to alanine scanning experiments. These experiments are very important as they
provide crucial data regarding the interactions between OSM and OSMRβ, for which a
crystal structure has not been obtained. First, Deller and coworkers identified amino acid
residues at site II of OSM responsible for OSM-gp130 binding. It was found that the
following four amino acid residues were responsible: Gln16, Gln20, Gly120, and
Asn124. While the Gln16Ala mutant seemed to have affected OSM binding the least, the
mutation of the other three amino acids caused the mutants to experience a significant
loss in binding ability. Next, the authors explored how specific mutations of amino acids
in site III of OSM altered its ability to bind to OSMRβ. It was found that both Phe160
and Lys163 were critical for stabilizing the OSM-OSMRβ binding event.
Both site II and site III mutants were subjected to a competitive binding assay that
assessed their ability to displace biotin-labeled OSM. Site II mutants were used to
displace biotinylated OSM from an immobilized gp130 receptor, while site III mutants
were used to displace biotinylated OSM from a gp130/LIFR fusion protein receptor. In
this experiment, the authors introduced increasing concentrations of OSM alanine
mutants to the biotinylated WT OSM bound to an immobilized gp130 receptor. Then, the
optical density was measured at 490 to observe the amount of biotinylated WT OSM
bound to the gp130 receptor. If the biotin-labeled WT OSM is displaced from the
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receptor complex, then the optical density measurements taken at 490 nm should
decrease in accordance with the population of displaced WT OSM.
The authors reported “activity values” for the competitive binding assays as IC50
quotients, where the IC50 of the mutant was divided by the IC50 of the biotinylated WT
OSM (IC50 mutant/IC50 WT OSM). To clarify, IC50 refers to the concentration of mutant
or WT protein required to elicit a 50% inhibition of binding of WT biotinylated OSM.
The Gln20Ala, Gly120Ala, and Asn124 (site II) mutants were observed to have activity
values of 90, > 100, and > 100, respectively. This translates to a 90-fold increase in the
IC50 for the Gln20Ala mutant and a greater than 100 fold increase in the IC50 values for
the Gly120Ala and Asn124Ala mutants. The Phe160Ala and Lys163Ala (site III) mutants
were both observed to have activity values > 100. This translates to a greater than 10,000fold increase in IC50 values for both mutants.
Second, site II and site III mutants were subjected to a cell-survivability assay that
measured their ability to induce cellular proliferation in Ba/F3 cells. Site II mutants were
used to stimulate Ba/F3 cells transfected with human gp130/LIFR, and site III mutants
were used to stimulate Ba/F3 cells transfected with human gp130/OSMRβ. This
experiment works on the premise that for the Ba/F3 cells to survive and multiply, the
gp130/OSMRβ or gp130/LIFR complex must be stimulated by OSM.5 In this experiment,
the authors introduced increasing concentrations of mutants to the Ba/F3 cells to observe
a change in optical density measured at 570 nm. If the measured optical density does not
increase, then receptor stimulation by OSM is not occurring.
The authors reported “activity values” for the Ba/F3 cell-survival assays as EC50
quotients, where the EC50 of the mutant is divided by the EC50 of WT OSM (EC50
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mutant/EC50). EC50 refers to the concentration of mutant required to elicit a response
equal to 50% of the maximal response of WT OSM. Gln20Ala, Gly120Ala, and
Asn124Ala (site II) mutants were observed to have activity values of 30, > 10,000, and >
10,000 respectively. This translates to a 30-fold increase in EC50 for the Gln20 mutant
and a greater than 10,000-fold increase in EC50 values for both Gly120Ala and Asn124
mutants. The Phe160Ala and Lys163Ala (site III) mutants were both observed to have
activity values > 10,000. This translates to a greater than 10,000-fold increase in EC50
values for both mutants.
Collectively, the assays suggest that Asn124, Gly120, and Gln20 are a core set of
solvent-exposed amino acids necessary for OSM-gp130 binding. When either of these
amino acids was mutated, a large decrease in affinity and Ba/F3 cell survivability was
observed. In addition, Phe160 and Lys163 were found to be absolutely necessary for
OSM’s ability to bind to OSMRβ and LIFR, as mutation of these amino acids resulted in
the inability to displace WT OSM from a gp130/LIFR fusion protein and completely shut
down OSM signaling in Ba/F3 cells.
In 2018, Adrian-Segarra and coworkers revealed a structural motif at site III of
OSM that was necessary for stabilizing the binding interaction between OSM and
OSMRβ. This was termed the FXXK motif.2 Similar to the work accomplished by Deller
and coworkers in 2000, the study's main objective was to replace specific residues with
alanine and evaluate the function of the OSM mutants. Site-directed mutagenesis of OSM
was performed by full-plasmid amplification, and E. coli was used to express the
mutants. The mutants were then purified and used to stimulate A375 melanoma cells to
measure OSMRβ activity or human choriocarcinoma cells to measure LIFR activity.
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Afterward, the amount of phosphorylated STAT3 (pSTAT3) was quantified by band
visualization of horse radish peroxidase-conjugated secondary antibodies. The amount of
pSTAT in the cell lysates was used as a metric to identify the degree of OSM signaling.
In addition to the crucial Phe160 and Lys163 residues previously identified by
Deller and coworkers, mutation of the amino acids Tyr34, Gln38, Leu40, Lue45, and
Cys49 were found to reduce pSTAT3 expression in A375 cells greatly. Interestingly, the
Leu40 and Cys49 mutants also caused a reduction of pSTAT3 expression in human
choriocarcinoma cells, which means that these amino acids are necessary to activate both
type I and type II OSMR complexes. These data suggest that the residues identified in
this experiment should be considered as targets in site III of OSM. Figure 2.2 summarizes
the key amino acids that were identified in the alanine scanning experiments performed
by Adrian-Segarra and coworkers, and Deller and coworkers.

Figure 2.2

Alanine scanning experiments identify key amino acids

(A) A top view of OSM overlooking site III depicts the amino acids that were identified to participate in OSMOSMRβ binding. While Phe160 and Lys163 were identified by Deller and coworkers, Tyr34, Gln38, Leu40,
Lue45, Cys49, Phe160, Lys163 were identified by Adrian-Segarra and coworkers. (B) A side view of site II on
OSM shows Asn124, Gly120, Gln20, and Gln16, which have been identified by Adrian-Segarra and coworkers as
core set of residues necessary for gp130 binding.
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In addition, Pro153 and Gly39 mutants were also observed to shut down OSM
signaling in A375 cells completely, but their ability to stimulate human choriocarcinoma
cells remained unaltered. It is important to note that the point mutations of these residues
most likely caused a change in characteristic structural rigidity necessary for OSM to
bind to OSMRβ preferentially over LIFR. For example, Gly39 and Pro153 are commonly
found in turn and loop structures of proteins.6 The mutagenesis of these most likely
caused a conformational change in OSM, rendering it unable to bind to OSMRβ yet still
able to bind to LIFR. In conclusion, the data generated by Adrian-Segarra and coworkers
agree with previous findings by Deller and coworkers.
2.2.3 Computational Alanine Scanning Experiments of OSM
Molecular simulation experiments performed by Du and coworkers have given
insight as to what residues greatly contribute to the binding interaction at the
OSM/OSMRβ interface.4 As the structure of OSMRβ is unknown, the authors
constructed a protein-protein binding region of OSMR that mimics the structure of LIFR.
After the OSMRβ construct was virtually generated, a per-residue energy decomposition
analysis was performed for the OSM/OSMRβ complex to reveal the energy contribution
of single amino acid residues. The amino acids that were predicted to have an energy
contribution more negative than -1.0 kcal/mol were classified as important. The perresidue binding energy decomposition predicted four residues in OSM that have already
been identified in the literature to be critical to OSM-OSMRβ binding.2 In agreement
with Adrian-Segarra and coworkers, Gly39, Leu40, and Leu45 in the AB loop, and
Phe160 in the D helix were identified as significant contributors. Furthermore, six
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additional amino acid residues were identified as playing an important role in OSMOSMRβ binding: Arg36, Asp41, Val42, Arg100, Leu103, and Gln161.
Next, Du and coworkers conducted computational alanine scanning experiments
on the residues that were significant contributors to the OSM-OSMRβ binding interaction
to discover hot spots between the proteins. The computational experiments revealed that
Arg100, Phe160, Leu103, and Gln161 contributed free energies of binding more than 2
Kcal/mol. As such, these amino acids were deemed particularly important for stabilizing
the OSM/OSMRβ complex. One of the hot spots was identified as a hydrogen-bond
between Arg100 of OSM and Asp262 of OSMRβ. In addition, the authors identified
another hydrogen-bond hot spot between Gln161 and Ser223. Lastly, a π-π interaction
between Phe160 of OSM and Tyr214 of OSMRβ was identified as a hot spot as well.
Table 2.1 summarizes which amino acid residues have been identified in the primary
literature to contribute to site II or site III binding of OSM. Notably, the amino acids
listed in the site III column present themselves as potential targets as these are shown to
stabilize the binding interaction between OSM and OSMRβ.
Table 2.1

Summary of key amino acids at sites II and III of OSM

In vitro and in silico alanine scanning experiments identify amino acids that participate in OSM-gp130 or OSMOSMRβ binding.

In vitro alanine
scanning
experiments
In silico alanine
scanning
experiments

Site II amino Acids
Gln16, Gln20, Gly120,
Asn124

Site III amino Acids
Tyr34, Gln38, Leu40, Lue45,
Cys49, Phe160, Lys163

N/A

Arg36, Leu40, Asp41, Val42,
Leu45, Arg100, Leu103,
Phe160, Gln161
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2.3 Identification of lead SMIs Targeting OSM
2.3.1 Identification of OSM-SMIs
Considering the supporting evidence from the alanine scanning experiments and
previous work accomplished by Dr. Danny Xu identifying druggable sites on OSM, site
III of OSM was the most favorable binding site to target for inhibition by SMIs. So, Dr.
Matt King (Boise State University) and Dr. Danny Xu conducted a high-throughput
virtual screening of approximately 1.65 million compounds from the National Cancer
Institute open database and ZINC databases using AutoDock 4.2 to identify 26
prospective SMIs. The compounds were predicted to have KD values less than 10 μM and
free energies of binding less than -5.0 kcal/mol.
As seen in Figure 2.3, the twenty-six potential lead compounds were purchased
and subjected to an ELISA by researchers in the Jorcyk lab at Boise State University. As
previously discussed in section 1.3, OSM binding initiates a phosphorylation cascade
wherein STAT3 proteins become phosphorylated by JAK proteins. The ELISA
experiments measure relative pSTAT3 expression in cell lysates using antibodies that
specifically target pSTAT3. So, pSTAT3 can serve as a metric for OSM-induced
signaling. To conduct the assay, recombinant human OSM was incubated for 1 hour with
or without SMI and was used to stimulate T47D human breast cancer cells. The no
treatment cell group (NT, white) received no OSM, resulting in a group that serves as a
baseline value for pSTAT3 expression. The OSM cell group (OSM, black) received
OSM, which serves as a maximum amount of pSTAT3 expression. The experimental
groups (gray) represent cells treated with OSM incubated with the according SMI. The
closer the experimental value of pSTAT3 expression levels is to that of the no treatment

54
group, the better the lead compound. Three of the compounds from the assay were chosen
to be optimized: SMI-8, SMI-10, and SMI-26. Even though SMI-23, SMI-24, and SMI25 were identified as lead compounds by their ability to inhibit OSM signaling, they were
not chosen to be further optimized.

Figure 2.3

ELISA results of the 26 lead compounds

A sandwich ELISA using T47D breast cancer cells was conducted in order to determine the inhibitory effects of
the computationally predicted SMIs. Recombinant OSM was treated with SMIs (grey) for 1 hour and then used to
stimulate T47D cells for 30 minutes. Phosphorylated STAT3 protein (pSTAT3) levels were quantified in the
resulting cell lysates. No treatment (white) refers to background levels of pSTAT3 in untreated cells. OSM
treatment (black) refers to the maximum pSTAT3 expression in cells. (n = 3, mean ± SD by one-way ANOVA).

Based upon the pSTAT3 ELISA results, SMI-8 quickly emerged as an ideal lead
candidate. Unfortunately, there were several concerns with the possible toxicity of SMI-8
as it possesses problematic functional groups. The dienes are predicted to be reactive as
the conjugated system allows the molecule to be a Michael acceptor. This is not
desirable, as this could result in toxic side effects. In addition, the synthesis is not
stereoselective as the dienes isomerize upon synthesis, rendering it impossible to
determine which isomers are generated. Therefore, the goal of this research was to design
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and make compounds that were like SMI-8 while deleting or changing any functional
groups that were predicted to be toxic.
2.4 Synthesis and Computational Modeling Results of SMI-8 and Analogs
2.4.1 Synthesis and Computational Modeling of SMI-8
The synthesis of SMI-8 is depicted in Figure 2.4. First, acid-catalyzed
bromination at the 4-position of the ethyl-acetoacetate starting material afforded the
unstable intermediate ethyl 4-bromoacetoacetate. The bromoalkane was then reacted with
dithiooxamide to perform a 5-exo-trig cyclization that resulted in the bisthiazole
intermediate. Simultaneous saponification of the esters produced a dicarboxylate, which
was then acidified to afford the dicarboxylic acid. Finally, a Perkin reaction using transcinnamaldehyde afforded SMI-8.
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Figure 2.4

Synthesis of SMI-8

Virtual ligand docking experiments were conducted to identify key amino acids of
OSM that stabilize the binding events between the SMI-8 analogs and the protein. These
experiments were accomplished using the University of California San-Francisco’s
Chimera program, used for the interactive visualization of proteins.7 In addition,
AutoDock Vina 4.2 and the ff14SB forcefield were used to calculate the free energy of
binding (FEB) scores to predict how well the analogs bind to site III OSM.8 For the ease
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of reading, the complete set of free energy of binding scores is listed at the beginning of
Chapter 3.
Panel A in Figure 2.5 shows the surface interactions between SMI-8 and site III of
OSM, in which the FEB was predicted to be -6.5 kcal/mol. Panel B reveals which amino
acids of OSM are predicted to stabilize the binding event. Panel C is a simplified, 2dimensional representation of the stabilizing interactions that are predicted to occur.
Overall, two basic types of interactions stabilize the binding event. These include
hydrophobic interactions and hydrogen bond interactions. As seen in panel C, it is
predicted that the bisthiazole of SMI-8 forms a hydrogen bond to the positively charged
Lys163. In addition, one of the carboxylate groups of SMI-8 is predicted to hydrogen
bond to Ser101 and Arg100, while the other carboxylate group is predicted to hydrogen
bond to Asp41. It is hypothesized that the diene groups of SMI-8 wrap around a
significant portion of site III and contribute to hydrophobic interactions that stabilize the
binding event. One of the predicted interactions occurs between a diene group and a
hydrophobic groove of OSM containing Leu40, Leu45, and Phe160. This is hypothesized
to be an important interaction as Phe160 has been identified to be essential for OSM
signaling.2, 3 The other diene group is predicted to bury itself in a hydrophobic pocket
containing Pro93, Leu88, and Ala159. The overall energy of binding contribution of
these interactions is unknown, as these residues have not been identified in either in vitro
or computational alanine scanning experiments.
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Figure 2.5

Virtual docking of SMI-8 to OSM predicts key interactions

(A) A top-down view of OSM shows SMI-8 bound to site III, with a FEB score of -6.5 kcal/mol. (B) Distinct
amino acids shown are hypothesized to play a role in stabilizing the binding event between SMI-8 and OSM. (C)
A simplified, 2-dimensional representation of SMI-8 interacting with specific amino acids at site III of OSM is
illustrated. The semi-circles indicate hydrophobic pockets formed by non-polar amino acids, while the dashed
lines indicate hydrogen bond interactions.

Although SMI-8 has proven to be a potent and consistent inhibitor of OSMmediated JAK/STAT signaling, some significant issues regarding the physiochemical
properties of the compound render it a poor substrate in both in vitro and in vivo
experiments. For example, previous murine-based studies at BSU have used SMI-8 to
inhibit breast cancer metastasis, but it has proven challenging to dissolve completely in a
non-lethal vehicle. Therefore, it is worthwhile to use programs such as SwissADME to
predict drug-like qualities of orally available small molecule drugs. Figure 2.6 depicts
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some drug-like characteristics and pharmacokinetics of SMI-8 predicted by
SwissADME.9

A

B

Figure 2.6

SwissADME predicts physiochemical properties of SMI-8

(A) SwissADME generates a bioavailability radar, which predicts several physiochemical properties of the SMI.
These properties include lipophilicity (LIPO), size (SIZE), polarity (POLAR), solubility (INSOLU), flexibility
(FLEX), and saturation (INSATU). (B) The BOILED-egg diagram shows the predicted lipophilicity and polarity
of small molecules in a cleverly designed manner. The y-axis corresponds to lipophilicity (WLOGP) and the xaxis corresponds to polarity (TPSA). The blue dot indicates the predicted polarity and lipophilicity characteristics
of the SMI.

According to SwissADME, SMI-8 is predicted to have poor drug-like qualities.
There are six important physiochemical properties in drug discovery and design:
lipophilicity (LIPO), size (SIZE), polarity (POLAR), solubility (INSOLU), flexibility
(FLEX), and saturation (INSATU). According to the graph in panel A, if the red dot falls
outside of the red-shaded area on the bioavailability radar, then the drug is considered to
have a sub-optimal score for that physiochemical property. It is clear that SMI-8 exhibits
unfavorable drug-like qualities when it comes to saturation and polarity. That being said,
there are some physiochemical properties that can be argued to be less important. For
example, one such rule states that the molecular weight of an orally available drug should
be no more than 500 g/mol.10 However, a paper published in 2014 identified at least 182
approved drugs have a molecular weight greater than 500 g/mol.11 In contrast, one of the
more important properties includes lipophilicity, which is experimentally measured as the
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logarithm of the partition coefficient between n-octanol and water (log Po/w).12
Lipophilicity is a critical factor in the success of a drug, as this characteristic governs
absorption, distribution, metabolism, excretion, and toxicity; these properties are referred
to collectively by the acronym ADMET. Lipophilicity is considered to be the most
predictive physiochemical property out of any of them when it comes to the future
success of an oral drug.13
Panel B in Figure 2.6 shows the predicted gastro-intestinal solubility of an orally
ingested compound in what is called a BOILED-Egg (Brain or intestinal estimated
permeation method) diagram.14 The yellow region of the egg shows the parameters in
which the drug can pass through the blood-brain barrier. The white region shows the
parameters in which the drug can be absorbed into the bloodstream through the intestines.
The blue dot indicates the predicted polarity and lipophilicity characteristics of the small
molecule. The diagram reveals that SMI-8 would not be well absorbed by the intestines if
administered orally, as the blue dot representing the compound falls outside of the
optimal parameters. Considering the reasons discussed in this section, there were changes
that needed to be made to SMI-8 that would allow for more favorable drug-like
properties.
2.4.2 Synthesis and Computational Modeling of SMI-8S
The first step in making a less toxic analog of SMI-8 was to replace the sp2
hybridized carbons in the dienes with sp3 hybridized carbons. Doing so would not only
overcome the issues with the stereoselective synthesis of the dienes, but it would also do
away with the undesired toxicity of the Michael acceptors. However, it introduces two
new stereocenters, which results in the possibility of forming a total of three
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stereoisomers, the (R,S) meso compound and the enantiomeric (R,R) and (S,S) pair. In
spite of this, a saturated version of SMI-8, SMI-8S, was targeted. Molecular docking
found favorable binding to the protein, and the synthesis was expected to be
straightforward (Figure 2.7). In the first step of panel A, alkylation of the diketone was
achieved in 68% yield using tetra-n-butylammonium iodide (TBAI) as a Finkelstein
reaction catalyst, dimethoxyethane (DME) as the solvent, and 3-phenylpropyl bromide as
the electrophile. The halogenation of the carbonyl α-carbon afforded the brominated
intermediate, which was then heated with dithiooxamide in ethanol. The resulting
bisthiazole was obtained in 59% yield and subsequently saponified to afford SMI-8S in
38% yield. It is unknown whether the compound was synthesized as the meso compound,
as an enantiomeric mixture, or a combination of the three.
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Figure 2.7

Synthesis and docking of SMI-8S

(A) SMI-8 was synthesized in 4 steps. (B) Virtual ligand docking predicted that SMI-8S binds to site III of OSM
with a FEB of -6.3 kcal/mol. The meso compound is represented in this binding pose.

It was hypothesized that SMI-8S would still maintain structural features that
allowed it to bind to OSM in the same fashion as SMI-8. According to panel B of Figure
2.7, it is predicted that SMI-8S participates in similar hydrogen bonding interactions and
hydrophobic interactions that are observed in the virtual docking of SMI-8. The SMI-8S
structure in panel B is depicted as the meso compound, which was calculated to have a
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free energy of binding score of -6.3 kcal/mol. The (R,R) and (S,S) enantiomers were
calculated to have binding scores of -6.0 kcal/mol and -6.2 kcal/mol, respectively. In
contrast to the rigid diene structure of SMI-8, it is possible that the phenylpropyl side
chains of SMI-8S can adapt to several different binding poses in site III; However, it is
currently unknown which pose(s) of the side chains is/are most energetically favorable.
SwissADME was also used to analyze SMI-8S to predict its physiochemical
properties and gastrointestinal absorption (Figure 2.8). Even though SMI-8S was
predicted to be an overall worse drug in respect to physiochemical properties, the main
goal of the synthesis was to determine if the dienes play a crucial role in binding SMI-8
to site III of OSM. As such, predicted physiochemical properties were not a significant
concern at this point in the project. According to panel A in Figure 2.8, SMI-8S was
predicted to be considerably worse in all categories besides saturation (INSATU).
Saturation is simply the fraction of carbons that are sp3 hybridized in the entire structure.
According to SwissADME, an optimal saturation is that in which the small molecule
contains no less than 25% of its carbons as being sp3 hybridized. The lipophilicity of
SMI-8 is predicted to be very poor as well. Since lipophilicity is the most critical factor in
determining the success of an oral drug, SMI-8S is less likely to exhibit favorable
ADMET qualities. The BOILED-Egg diagram in panel B predicts that SMI-8S would be
poorly absorbed in the gastrointestinal tract, as the blue dot representing the compound
does not fall within the acceptable parameters.
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A

B

Figure 2.8

SwissADME predicts physiochemical properties of SMI-8S

(A) SwissADME generates a bioavailability radar, which predicts several physiochemical properties of the SMI
being analyzed. (B) The BOILED-egg diagram shows the predicted lipophilicity and polarity of small molecules
in a cleverly designed manner. The y-axis corresponds to lipophilicity (WLOGP) and the x-axis corresponds to
polarity (TPSA). The blue dot indicates the predicted polarity and lipophilicity characteristics of the SMI.

2.4.3 A Potent Moiety is Identified
While efforts were focused on the design and synthesis of SMI-8 analogs, other
researchers in the Warner lab synthesized potent SMIs based on the SMI-10 and SMI-26
structures seen in Figure 2.9. This work identified a potent aryl amide moiety, which
contains a carboxylic acid at the 3-position of the benzene ring. In panel A, the only
structure changing in the SMI-10 scaffold is the aryl amide group at the 2-position of the
furan. From the fluorescence quenching data listed in accordance with the Ar groups, it is
clear to see that the most potent inhibitor in the series of SMI-10 analogs includes this
moiety (KD = 4 ± 1 µM). In panel B, the only structure changing in the SMI-26 scaffold
is the aryl group at the 4-position of the quinoline core. Like SMI-10, SMI-26 is observed
to bind to OSM with a greater affinity when this moiety is part of the structure (KD = 6 ±
1 µM). These trends observed from structurally different SMIs suggest that this specific
aryl amide should be included in future analogs. Therefore, it was decided that this amide
would be integrated into the rest of the SMI-8 analogs described after this point.
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Figure 2.9

Fluorescence quenching data reveals a potent moiety

(A) KD values of SMI-10 analogs were found using a fluorescence quenching assay, where Ar = aryl. (B) KD
values of SMI-26 analogs were found using a fluorescence quenching assay, where Ar = aryl.

2.4.4 Synthesis of SMI-8A4 Analogs
In order to explore non-branched bisthiazole analogs, three SMIs were
synthesized. These new compounds varied from the original SMI-8 structure in 2 specific
ways. First, they did not include any branching at the alpha carbon of the carbonyl group.
Instead, these remained as methylene groups. This avoided the generation of
stereocenters. Second, the carboxylic acids were replaced with substituted aryl amide
moieties. It was hypothesized that simultaneous amidations would be relatively
straightforward. Molecular modeling of the three compounds revealed free energy of
binding scores that ranged from -6.6 to -7.7 kcal/mol.
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The synthetic route of the bisthiazole analogs is shown in panel A of Figure 2.10,
where elemental bromine and acetic acid were used to brominate the carbon at the 4position of the ethyl acetoacetate starting material. The bromoalkene was then heated
with dithiooxamide in ethanol to produce the bisthiazole intermediate. Afterward, the
esters were saponified to produce the dicarboxylic acid. Attempts to make the reactive
acid chloride intermediate with thionyl chloride proved unsuccessful as the dicarboxylic
acid material was sparingly soluble in dichloromethane. In addition, previous attempts
using ([(1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide
hexafluorophosphate]) (HATU) resulted in a blue/black solid that precipitated out of the
DMF solvent. Finally, benzotriazol-1-yloxytris(dimethylamino)phosphonium
hexafluorophosphate (BOP) was successfully used to form the reactive ester intermediate
and install the aryl amide. Finally, panel B shows the saponification step that was unique
to one of the three SMIs. All of the SMI-8A analogs prepared to date are presented in the
next chapter in table 3.1.
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Figure 2.10

General synthesis of SMI-8A4 analogs

(A) Three bisthiazole compounds were constructed according to the general synthetic route, where “Ar”
indicates the presence of a substituted aryl amide. (B) One of the three compounds synthesized was saponified.

2.4.5 Synthesis and Computational Modeling of SMI-8H Analogs
A new scaffold was designed that resembled half of SMI-8S while incorporating
new fragments at the 2-position of the thiazole. This scaffold allowed for the generation
of a small library consisting of twenty-two analogs. The general synthetic route can be
seen in panel A of Figure 2.11. First, commercially available 2-aminothizole-4carboxylic acid was treated with tert-butyl nitrite to form the diazonium intermediate,
which reacts with Cu (II) bromide to form the 2-bromothizole-4-carboxylic acid. Next, an
enolate alkylation was performed in order to form a new carbon-carbon bond at the αcarbon of the carbonyl. One equivalent of Hexamethylphosphoramide (HMPA) was
introduced in the enolate alkylation reaction with the aim of improving the yield by
sequestering the Na+ cations and rendering the enolate more reactive.15 Unfortunately,
only an 8% increase in yield was observed when HMPA was added versus when it was
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not. As a consequence of the non-enantioselective enolate alkylation, the intermediate
was collected as a racemic mixture, which resulted in “intermediate C.” In the next step
of the main synthetic scheme, saponification of the ester afforded the carboxylic acid.
Similar in structure to BOP, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5b]pyridinium 3-oxid hexafluorophosphate (HATU) was used to perform an amidation
reaction to afford “intermediate E.” R1 groups were installed by Pd(0) catalyzed carboncarbon coupling reactions to afford biaryl products, while R2 groups were installed by
nucleophilic aromatic substitution to afford aryl amine products. As seen in panel B, the
carbon-bromine bond in both intermediates C and E were reduced by Pd/C reduction in
the presence of H2 gas and then saponified. Acidification of the carboxylate groups
afforded two separate SMIs. It should be noted that the product obtained after the
reduction and subsequent saponification of intermediate C was named SMI-8S3 and is
therefore not identified as an SMI-8H analog. All of the SMI-8H analogs prepared to date
are presented in the next chapter in Figure 3.3.
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Figure 2.11

General synthesis of SMI-8H analogs

(A) R1 groups were installed using Pd (0) carbon-carbon coupling, while R2 groups were installed by
nucleophilic aromatic substitution, where Ph = phenyl. Two SMIs were synthesized via catalytic
hydrogenation of the brominated intermediate, followed by saponification.

According to the virtual docking experiments, the 8H analogs were consistently
observed to have lower free energy of binding scores than SMI-8 and SMI-8S. While
SMI-8 and SMI-8S exhibited free energy of binding (FEB) scores of -6.5 kcal/mol and 6.3 kcal/mol, respectively, the SMI-8H analogs were calculated to have FEB scores in the
range of -6.1 to -8.0 kcal/mol when docked to site III of OSM. Even though this
difference is not great, it suggests that the 8H analogs are predicted to bind to OSM just
as well as SMI-8 and SMI-8S.
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Although the new analogs were designed based on SMI-8 and contain a common
thiazole moiety, their structural differences are such that they may bind to different amino
acids at site III of OSM. In panel A of Figure 2.12, virtual docking experiments predicted
that SMI-8H11 interacts with the same important residues as SMI-8 and SMI-8S. Panel B
illustrates a simplified, two-dimensional interpretation of these binding interactions. A
hydrogen bonding interaction can be observed between Lys163 of OSM and the nitrogen
atom in the thiazole group of the SMI-8H11. The carboxylic acid on the aryl amide is
predicted to bury itself in a hydrophobic pocket containing Arg91 and Arg162. Unlike
SMI-8 or SMI-8S, SMI-8H11 is not observed to interact with as many hydrophobic side
chains of OSM. However, it is plausible that the phenyl group at the 2-position of the
thiazole and the Phe160 can still interact. Other fatty side-chain amino acids such as Ile37
and Leu98 were observed to form a hydrophobic groove to accommodate the
phenylpropyl chain. Overall, virtual docking experiments suggest that SMI-8H analogs
interact with the same critical residues as SMI-8 and SMI-8S.
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Figure 2.12

Virtual docking of SMI-8H11 to OSM predicts key interactions

(A) The amino acid that are predicted to stabilize the binding interaction between SMI-8H11 and site III of OSM
are illustrated. (B) A simplified, 2-dimensional illustration shows SMI-8H11 interacting with specific amino acids.
The semi-circles indicate hydrophobic pockets formed by non-polar amino acids, while the dashed lines indicate
electrostatic/hydrogen-bond interactions.
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2.4.6 Synthesis of 8M analogs
Rather than designing a scaffold from existing SMIs, the scaffold of SMI-8M was
constructed using a diversity-oriented synthesis approach, where different structural
moieties are changed to discover new lead compounds.16 So, SMI-8M was designed to
contain a thiazole as the core of the molecule, with the 2-position of the thiazole
appended with a variety of substituted phenyl groups. Unlike the analogs previously
discussed, the SMI-8M analogs exhibit minimal structural resemblance to SMI-8.
The SMI-8M analogs were constructed in three steps, as seen in Figure 2.13.
First, commercially available 2-bromo-4-thiazolecarboxylic acid was reacted with
Hünig’s base and HATU to form the reactive ester intermediate. Nucleophilic attack by
the 3-aminobenzoic acid afforded the amidation product in 69% yield. Next, Pd(0)
catalyzed carbon-carbon coupling formed a new bond between the carbon on the 2position of the thiazole and the according Ar group to give yields of 47-69%. Finally,
saponification followed by acidification yielded the desired carboxylic acid final products
in yields of 53-81%. All the SMI-8M analogs prepared to date are presented in the next
chapter in Figure 3.2.

Figure 2.13

General synthesis of SMI-8M analogs

Seven compounds were constructed according to the general synthetic route, where “Ar”
indicates the presence of a substituted aryl amide.
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2.5 Summary of Chapter Two
Sites I, II, and III of OSM were independently identified as ligand binding sites on
OSM. Targeting site III, a high throughput virtual screening was performed to identify
SMI-8 as a lead compound. In vitro and in silico alanine scanning experiments exposed
Tyr34, Arg36, Gln38, Leu40, Asp41, Val42, Leu45, Lys49, Arg100, Leu103, Phe160,
Gln 161, and Lys163 as amino acids that participate in stabilizing interactions between
OSM and one of its transmembrane receptors OSMRβ. In addition, computational
docking studies and protein modeling revealed plausible binding interactions between the
crystal structure of OSM and the virtually docked compounds. Upon synthesis and
evaluation by ELISA experiments, SMI-8 was discovered to be a potent inhibitor of OSM
signaling. The synthesis of SMI-8 and SMI-8S involved the generation of bisthiazoles
through a proposed 5-exo-trig cyclization. However, the potential toxicity and lack of
stereoselectivity of SMI-8 necessitated the design and synthesis of other analogs.
Therefore, 34 SMIs were synthesized, 25 of which resemble the structure of SMI-8. The
next chapter will contain a discussion of the several assessments used to determine the
binding strength and properties of the SMIs to OSM.
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CHAPTER THREE: ASSESSMENT OF SMI-8 ANALOGS TARGETING OSM
3.1 Overview of Chapter Three
This chapter includes the nomenclature of the SMIs synthesized in the previous
chapter, as well as the free energy of binding (FEB) scores calculated in the virtual ligand
docking experiments, where lower FEB scores indicate better binding OSM-SMI. In
addition, this chapter discusses the direct binding assays and cell-based inhibitory assays
used to assess the small molecules. As OSM has been identified to induce the JAK/STAT
pathway, levels of pSTAT3 expression in breast cancer cells can be measured to quantify
the degree of OSM signaling. Therefore, the SMI-8 analogs were subject to an ELISA
that measured their ability to inhibit OSM signaling in T47D human breast cancer cells.
In addition, a Western blot assay was used to assess the ability of SMI-8 to inhibit OSM
signaling in MDA-MB-231 human breast cancer cells. A fluorescence quenching assay
was used to determine the direct binding affinity of SMI-8 and SMI-8S towards OSM. A
chemical shift perturbation assay of SMI-8S was also accomplished to determine which
amino acids closely interact with the compound upon binding. Finally, attempts were
made to design a differential scanning fluorimetry experiment to rapidly determine
relative binding affinities in a library of compounds.
3.2 Nomenclature and Computational Binding Scores of SMIs
3.2.1 SMI-8A4 analogs
The naming system for the bisthiazole based analogs is relatively crude and
simple as a wide variety of structures were not synthesized. Therefore, unique names
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were given to the compounds rather than developing a systematic naming convention
more suitable for an extensive library. The “8A4” root of the analog name identifies that
an acetamide moiety was installed on the 4-position of the thiazole rings. Figure 3.1
shows the three analogs labeled with their according names. The 8A4 analog was the first
of its kind to be synthesized, so it was simply named as the basic root. The other two
analogs include a “Cl” or an “OMe” in the name to signify the presence of a chlorine or
methoxy group at the para position.

Figure 3.1

Structure and binding scores of SMI8H analogs

The figure depicts SMI-8A4 analogs along with their FEB scores.
AutoDock Vina 4.2 and the ff14SB forcefield were used to calculate the
free energy of binding (FEB) scores.

3.2.2 SMI-8M analogs
The “M” in the base of the analog stands for the German word “Männchen,”
which translates to “little/small men.” This was chosen because the 8M analogs are less
massive than SMI-8. The analogs were designed so that only the 2-position on the
thiazole was to be appended with different aryl groups. Therefore, the analogs are simply
numbered, starting at number one. Also, this numbering system reflects the relative
timeline in which the SMIs were successfully synthesized. For example, SMI-8M1 was
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the first compound of its kind to be synthesized and isolated. These structures, with their
according name and FEB scores, can be seen in Figure 3.2.

Figure 3.2

Structure and binding scores of SMI-8M
analogs

The figure depicts the structures of the SMI-8M analogs along with their according
FEB score.

3.2.3 SMI-8H analogs
The “H” portion in the base of the analog name stands for “half,” which is used to
describe its structure as being similar to half of SMI-8S. As the 2-position of the thiazole
was the only portion of the molecule that varied among the analogs, a simple numbering
system was used in order to differentiate them. Therefore, the analogs are numbered,
starting at number one. This numbering system reflects the relative timeline in which the
SMIs were successfully synthesized. For example, SMI-8H1 was the first compound of
its kind to be synthesized and isolated. These structures and their according names can be
seen in Figure 3.3.
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Figure 3.3

Structure and binding scores of SMI-8H analogs

(A) SMI-8H analogs were synthesized as either amines, or biaryl compounds. The numbers in the
top left portion of the cells refer to the number of the analog. (B) The free energy of binding scores
(FEB) are in units of kcal/mol and are listed to the right of the according compound.

3.3 Inhibitory Activity Studies
3.3.1 Enzyme-Linked Immunosorbent Assay
Introduced in the first chapter, phosphorylation of STAT proteins is an important
mechanism that occurs in the JAK/STAT signaling pathway mediated by OSM.1
Therefore, the quantity of pSTAT3 in cell lysates can serve as a metric for the degree of
OSM signaling. Figure 3.4 shows the basic concept of the sandwich ELISA experiment
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that was used to determine the relative expression of pSTAT3 in T47D breast cancer cell
lysates.2 To test the inhibitory effects of the SMIs, the wells of a 96-well plate are precoated with the pSTAT3 specific capture antibody (step 1). Next, the cell lysates are
introduced into the wells, whereupon pSTAT3 binds to the capture antibody (step 2).
Next, the primary antibody is introduced to “sandwich” the pSTAT3 protein between
itself and the capture antibody (step 3). Next, a biotin-labeled secondary antibody is
introduced into the wells where it binds to the primary antibody (step 4). Finally,
streptavidin-horse radish peroxidase binds to the biotin and catalyzes a reaction that
produces a specific color (step 5). The degree of coloring is then measured by probing the
optical density of each well at 450 nm.

Figure 3.4

Principles of a sandwich ELISA

(1) The wells are pre-coated with the pSTAT3 specific capture antibody (yellow). (2) The capture antibody binds
the specifically to pSTAT3 (red). (3) The primary STAT antibody (blue) then binds to the STAT protein, creating
a “sandwich”. (4) The biotin-labeled secondary antibody (green) is introduced, which binds to the primary
antibody. (5) Finally, streptavidin-horse radish peroxidase is introduced and catalyzes a reaction that produces a
blue color, which is measured by optical density.
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As seen in Figure 3.5, several of the SMI-8H analogs were subjected to sandwich
ELISA experiments where T47D breast cancer cells were treated with and without OSM.
The cells that were treated with OSM induced a maximum level of pSTAT3 expression,
and these levels were normalized to 1.0 (OSM, red). The pSTAT3 expression of cells that
were not treated with OSM (NT, white) serves as a baseline value. Next, the cells were
treated with the OSM and the SMIs to measure the extent of SMI-induced inhibition
(blue). So, if an SMI was exceptionally efficient in inhibiting OSM signaling, it would
lower the pSTAT3 expression level close or equal to that of the no treatment group.

Figure 3.5

ELISA of SMI-8 analogs

OSM was treated with SMI-8 analogs (Blue) for 1 hour and then used to stimulate T47D cells for 30
minutes. Phosphorylated STAT3 was quantified in the resulting cell lysates. No treatment (white) refers
to background levels of pSTAT3 in cells not treated with OSM. SMI-8 (black) is used as a positive
control (n=3, mean ± SD by one-way ANOVA; ****p <0.0001 compared to +IP with Dunnett’s multiple
comparisons test). SMI-8H4 and SMI-8H6 do not yet have an n = 3, precluding statistical analysis

Not all the analogs synthesized have been subjected to an ELISA experiment, yet
there are emerging structural activity relationships that can be identified. It is clear that
SMI-8 and SMI-8S both reduce pSTAT3 expression in the cancer cells to the point of the
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no treatment groups. The data suggest that the dienes are not critical for inhibiting OSM
signaling. So, it is likely that the structural rigidity of the dienes in SMI-8 is not
necessary. The 8M series of analogs was promising, as almost all performed as well or
better than SMI-8. The only outlier was SMI-8M3, which was predicted to have one of
the best FEB scores out of the series (-8.0 kcal/mol). Currently, there is not enough data
to propose a rationale for this disagreement. Besides this, the ELISA results agree with
the FEB scores of the SMI-8M analogs calculated by AutoDock Vina.
The inhibitory effects of the two 8A4 analogs are also comparable to SMI-8, as
they were able to reduce the pSTAT3 expression values equal to that of the no treatment
group. So, it is plausible that phenylpropyl groups in the structure might not be as
necessary as previously thought. It is hypothesized that these SMIs can inhibit pSTAT3
expression effectively due to the bisthiazole core, which is predicted to hydrogen bond to
Lys163. The ELISA results also agree with the results calculated by AutoDock Vina, as
SMI-8A4, SMI-8A4Cl, and SMI-8AOMe have FEB scores of -7.7, -6.6, and -7.0
kcal/mol, respectively. More need to be synthesized and tested to determine any
meaningful relationships between the structure and function of these analogs.
Since more SMI-8H analogs were synthesized and subjected to ELISA, it is easier
to observe trends with this group of compounds. Based on FEB scores, it was
hypothesized that an aryl group at the 2-position of the thiazole would increase ligand
affinity towards site III of OSM compared to one that did not contain an aryl group. So,
SMI-8H4 was synthesized to be negative control since it lacks an aryl group at the 2position of the thiazole. SMI-8H4 and SMI-8H11 were computationally predicted to have
FEB scores of -6.1 and -7.2 kcal/mol, respectively. The structures of both analogs can be
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seen in Figure 3.6. In agreement with the hypothesis, SMI-8H4 was proven to be a less
effective pSTAT3 inhibitor than SMI-8H11. This means that it is important for the 8H
analogs to contain an aryl group at the 2-position of the thiazole (Figure 3.6). As a
considerable amount of the analogs were within error of another in the ELISA
experiments, it is difficult to draw definitive structural activity relationship (SAR) trends.
However, the ELISA experiments tend to reflect the predicted binding scores of the
compounds.

Figure 3.6

Structures of SMI-8H4 and
SMI-8H11

3.3.2 Western Blot Assay of SMI-8
A Western blot assay is used to separate and identify a specific protein in a
mixture of proteins.3 A Western blot is performed by first separating the proteins by gel
electrophoresis and transferring them to a membrane that produces a band for each
protein present. The gel containing the bands is then incubated with specific antibodies
that will attach to the protein so it can be visualized. The thickness of the band is often
used to identify the concentration of the protein present when compared to a loading
standard.3 Western blot analyses were used to address two main concerns with the SMI
project. First, other pro-inflammatory pathways can be induced by OSM. In addition to
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the previously identified JAK/STAT pathway, OSM has been identified to induce the
pJNK, pERK, and pAKT signaling pathways.4 This is important to know, as the
aforementioned ELISA experiments only measure the phosphorylation of STAT3.
Second, pSTAT3 expression could be inhibited by a different mechanism that does not
involve the SMI binding to OSM. To determine the downstream signaling effects of
OSM inhibition and confirm that SMI-8 is binding to OSM to inhibit pSTAT3
expression, the Jorcyk lab conducted a Western blot assay in MDA-MB-231 human
breast cancer cells treated with and without SMI-8 (Figure 3.7). The cells treated without
OSM serve as a negative control (- lane), and the cells treated with OSM serve as a
positive control (+ lane). The cancer cells we also treated with SMI-8 that was incubated
with OSM for 1 hour (+SMI-8 lane). STAT3 and actin protein levels were used as
internal loading controls. The Western blot shows that the OSM incubated with SMI-8
failed to induce the phosphorylation STAT3, JNK, ERK, and AKT as all the bands are
gone or barely visible. This evidence supports the notion that other downstream proinflammatory signaling pathways are inhibited with the treatment of SMI-8. In addition,
it also shows that pSTAT3 inhibition by an alternative mechanism is not likely, especially
as the cells remain viable under experimental conditions.
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Figure 3.7

SMI-8 Inhibits OSM signaling in human
breast cancer cells

MDA-MB-231 human breast cancer cells were stimulated with (+ lane) or
without (- lane) OSM for 30 minutes. In addition, cells were treated with OSM
incubated with SMI-8.

3.4 Direct Binding Assays of OSM-SMIs
3.4.1 Fluorescence Quenching Assays of SMI-8 and SMI-8S
Even though the ELISA results were promising, it is necessary to measure the
binding affinities of the OSM-SMIs directly. Obtaining this information is essential as it
discloses compound affinity for a specific substrate and verifies that a direct binding
event is occurring. Obtaining KD values is a practical way to rank binding affinities for
SMIs.5 Researchers in the Warner group adopted a fluorescence quenching (FQ) assay
used by Charlier and Plapp that relies on the intrinsic fluorescence of one or more
tryptophan residues present in the protein.6 A local change in the environment of the
tryptophan residue can occur upon binding of the ligand. This change in environment can
be caused by an SMI binding closely or far away from the tryptophan residue.7 It was
found that OSM has a tryptophan (Trp187), so the FQ was deemed appropriate. In the
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experiment, a known amount of SMI is titrated into a cuvette containing a known amount
of OSM in a buffered solution. The cuvette holding OSM is then subjected to a 280 nm
wavelength of light, and fluorescence of the tryptophan is observed at 350 nm. Upon the
binding of SMI to OSM, a reduction of the fluorescence intensity is observed. The
fluorescence signal is then plotted against the SMI concentration added, and the data
𝑓𝑓

were fit to a modified Stern-Volmer function. The function is as follows: � � =
𝑓𝑓𝑜𝑜
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When subjected to the FQ assay, SMI-8 and SMI-8S returned KD values of 5 ± 1

μM and 14 ± 3 μM, respectively (Figure 3.8). KD is expressed as

[𝑆𝑆𝑆𝑆𝑆𝑆] [𝑂𝑂𝑂𝑂𝑂𝑂]
[𝑆𝑆𝑆𝑆𝑆𝑆⋅𝑂𝑂𝑂𝑂𝑂𝑂]

, where [SMI]

and [OSM] are the concentrations of ligand and receptor unbound, and where
[SMI⋅OSM] is the concentration of ligand bound to the receptor. So, a smaller KD is
favorable. These results help answer one of the most important questions posed at the
inception of the SMI-8 project: do the dienes significantly contribute to the ability of
parent-8 to bind to OSM? Considering that the KD values measured for SMI-8 and SMI8S are close, the dienes are not critical. Therefore, future analogs based on SMI-8 should
not include the dienes if structural changes can be made to make up for the observed
slight loss in binding affinity.
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Figure 3.8

Fluorescence quenching assays of SMI-8 and SMI-8S

(A) Four separate polymethylmethacrylate cuvettes were filled with 750 μL protein/buffer solution containing 50
mM sodium phosphate, 100 mM sodium chloride, and 1.0 μM recombinant OSM (pH = 6.6). Three of the cuvettes
were titrated with 0-100 μM SMI, while the fourth cuvette was titrated with DMSO to serve as a blank. The y-axis
is the measured fluorescence signal of the sample containing SMI divided by the fluorescence signal of the DMSO
blank (f/fo) and the x axis is the concentration of SMI added. (B) SMI-8 and SMI-8S were measured to have KD
values of 5 ± 1 μM and 14 ± 3 μM, respectively (n = 3).

Unfortunately, the remainder of the SMI-8H analogs could not successfully be
tested by the FQ assay as they fluoresce at 350 nm once excited at 280 nm. Typically,
subtractions can be made to the dataset to account for the addition of fluorescence
observed by the small molecule, but corrections did not produce reliable results for the
SMI-8H analogs. This is most likely due to a synergistic effect occurring between the
SMI and the protein, where the OSM-SMI complex fluoresces at a higher wavelength in
comparison to either the SMI-8H analog or the OSM protein alone. Unfortunately, these
results demonstrated that an alternative method must be used to obtain binding affinities
for these and other SMIs.
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3.4.2 Chemical Shift Perturbation Experiment of SMI-8S
A Chemical shift perturbation (CSP) experiment is a two-dimensional NMR
method of monitoring chemical shifts of amide protons in an isotopically enriched protein
upon ligand addition. CSP experiments can reveal both the binding location on the
protein and the affinity of the ligand.8 This experiment is accomplished by obtaining a
15

N/1H heteronuclear single quantum coherence (HSQC) NMR spectrum of the protein

without any ligand added. Next, the protein solution in the NMR tube is titrated with a
known ligand concentration, and an HSQC spectrum is obtained for multiple titration
points. This results in an overlayed series of HSQC spectra that reveal which amino acids
experience a change in their magnetic environment upon the addition of the SMI.
While CSP experiments provide rich binding information and can provide KD
values, the cost associated with needing large quantities of 15N labeled protein precludes
testing a complete library. As such, SMI-8 and SMI-8S, which have both successfully
inhibited OSM in ELISA experiments and have KD values in the low micromolar range,
were selected for CSP assays. Aaron Ajeti (Lisa Warner group) performed these titrations
with protein obtained from the Biomolecular Research Center, using a protocol
developed by Dr. Lisa Warner and coworkers.2 Unfortunately, the CSP titration with
SMI-8 was not successful as the SMI/OSM complex formed an orange-colored
precipitate upon addition. As a result, the protein signal was diminished to the point
where obtaining an accurate ppm shift was not possible.
The CSP titration with SMI-8S was a success as there were no solubility issues.
An overlay of the HSQC spectra obtained in the SMI-8S CSP experiment can be seen in
Figure 3.9. It was observed that the chemical shifts of several amino acids were perturbed
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in the HSQC spectra upon the addition of increasing amounts of SMI-8S. By comparing
the chemical shifts to a previously reported NMR spectrum of a glycosylated OSM
construct,9 three of the amino acids were tentatively identified as Gln90, Arg91, and
Leu92 with chemical shifts at (7.4, 117), (7.3, 116), and (6.9, 117), respectively. Notably,
these same amino acids were also perturbed when OSM was titrated with structurally
unrelated SMIs that were also designed to bind to site III.2 This is an important finding
for two reasons. First, it validates the original computational modeling used to design
structurally different molecules that specifically target site III of OSM. Second, the data
suggest that the SMIs bind near Gln90, Arg91, and Leu92 at site III of OSM.2

Gly 166
Increasing [8S-SMI]

]

Gln90

Arg91

15N

Leu92

[ppm]

Increasing [

Leu82

1H

Figure 3.9

[ppm]

Chemical shift perturbation assay of SMI-8S

0-180.9 μM final concentrations of SMI-8S were added to an NMR tube containing the following components:
600 μL recombinant OSM, 100 μM OSM, 50 mM sodium phosphate, and 100 mM sodium chloride. In the figure,
a red to blue shift indicates increasing SMI concentration. The spectral overlay shows cross peaks shifting red to
blue with increasing 8S-SMI concentration. The 5 amino acids that have been identified include Leu92, Gln90,
Arg91, and Gly166, with chemical shifts of (6.9, 117), (7.4, 117), (6.3, 116), and (6.9, 117) ppm, respectively.
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Not all amino acid CSPs could be identified, as several of the observed shifts are
not isolated enough to be compared to known chemical shift values. However, CSPs for
Leu82 and Gly166 were identified at (8.7, 127) and (7.9, 111) ppm, respectively. This
CSP observed for Leu82 is quite interesting, as Leu82 lies within the middle portion of
the middle of the protein. It is hypothesized that some non-specific event binding might
cause this perturbation as this amino acid is not located in site III of OSM, according to
the crystal structure visualized in USCF Chimera.10 In addition to consulting the
previously known chemical shifts for a glycosylated construct of OSM, NMRFAMSPARKY11 was used to upload and visualize 1H/15N HSQC assignments for OSM.
Known OSM 1H/15N HSQC assignments were retrieved from the Biological Magnetic
Resonance Data Bank (OSM protein #4063) and overlayed with the experimental data to
verify overlapping peaks.12
3.4.3 Differential Scanning Fluorimetry Experiments of SMI-8 Analogs
The thermal stability of a protein in solution is influenced by several different
soluble components participating in non-specific binding events.13 Notably, small
molecule ligands have been reported to influence protein stability by increasing or
decreasing the melting temperature (TM) of a protein, which is indicative of a binding
event.14 Differential scanning fluorimetry (DSF) is a common drug discovery method that
measures a protein’s TM upon the presence and absence of a ligand.14 Experiments by
Holdgate and Ward show that the relative binding affinity of compounds with similar
physicochemical properties can be determined by DSF.15 Therefore, DSF was deemed to
be an appropriate assay to determine the relative binding affinities of the SMI-8H
analogs.
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Figure 3.10 depicts the principles of a typical DSF experiment. As the stability of
most proteins decreases with increasing temperature, they will start to melt (denature).
The TM of a protein is identified as the inflection point of the curve where Gibbs free
energy of the protein (ΔGu) becomes zero. At this point, the unfolded and folded protein
population states are in equilibrium.16 Upon protein unfolding, a dye called SYPRO
Orange binds to the hydrophobic region of the protein, after which it fluoresces.14 In the
Figure, the black curve represents a hypothetical melting curve of OSM without any SMI,
while the cyan curve represents a hypothetical melting curve of OSM that has been
melted with SMI. The difference between the two melting points of the control and
experimental group is what is referred to as a change in melting temperature, or thermal
shift (ΔTM). Furthermore, ligands that bind to the protein in the native state and increase
the TM are referred to as N-binders. In contrast, ligands that preferentially bind to the
unfolded state of the protein are referred to as U-binders.17 However, one should be
aware of the limitations that exist when interpreting ΔTM for purposes of calculating
binding affinities. The magnitude of the ΔTM can vary for different compounds with the
same affinity. Therefore, DSF should be used in conjunction with other binding affinity
experiments as it only identifies if the compound can or cannot bind to the protein in
question.14
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Figure 3.10

Principles of DSF

The black curve in represents a hypothetical melting curve of OSM without SMI (black sphere), while
the cyan curve represents a hypothetical melting curve of OSM with SMI. Upon the unfolding of the
protein in either curve, SYPRO Orange (orange sphere) binds to the hydrophobic portion of the protein
and fluoresces. The melting temperature of the protein (TM) is identified as the inflection point of the
curve. A Shift in the TM of the protein (ΔTM) indicates a binding event.

In order to find a suitable concentration of OSM that would give a reliable
fluorescence signal, a dilution series experiment was performed without any SMI. An
adequate fluorescence signal was achieved using concentrations of OSM anywhere from
8-16 μM as concentrations of 2 and 4 μM of OSM were found to give a weak
fluorescence signal. Preliminary experiments (data not shown) using a structurally
unrelated SMI being studied in the Warner lab (SMI-10B)) at a final concentration of 1:1
SMI to OSM did not elicit an observable ΔTM, so an investigation using various
concentrations of SMI-10B was conducted (Figure 3.11). Unfortunately, SMI-8 was not
chosen as the compound was not soluble at the concentrations that needed to be tested.
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Panel A shows the raw fluorescence obtained during the experiment as a function of
temperature, while panel B shows the first derivative of the raw fluorescence as a
function of temperature, in which the maximum y-value signifies the melting point of the
protein.

Figure 3.11

SMI-10B stabilizes OSM

SMI-10B was added at concentrations of 15, 30, 45, 60, 75, and 90 μM to an aqueous buffer solution containing
15 μM OSM, 50 mM sodium phosphate, and 100 mM sodium chloride. (A) The raw fluorescence was obtained as
a function of temperature. The dashed black lines indicate the melting points for each specific replicate. (B) Graph
B is the first derivative of the raw fluorescence as a function of temperature (n = 3).

Without any SMI-10B added, the OSM control group (red) experienced an
average TM of 66.29 °C. Interestingly, the only concentration of 10B that seemed to cause
a shift was 90 μM (orange), which shifted the average TM of OSM to 75.37 °C. This
resulted in a calculated ΔTM of +9.08 °C. As the measured ΔTM is positive, this likely
means that SMI-10B binds and stabilizes the native state of OSM, which classifies it as
an N-ligand.17 It seemed peculiar that any concentration lower than 90 μM did not elicit a
shift in the TM of OSM. DSF experiments performed by Cimmperman and coworkers
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describe a “saturation effect,” which can occur when a ligand does not elicit an expected
ΔTM.17 This can happen if the ligand is partially binding to the unfolded state of the
protein, or it can be a result of ligand insolubility. Nevertheless, the data from this
experiment suggested that SMIs should be subjected to DSF with no less than a 6:1 SMI
to OSM ratio.
Figure 3.9 shows the DSF data that were obtained when SMI-8H3 and SMI-8H6
were heated with OSM in a DSF experiment. Without any SMI added, the OSM control
group (red) experienced an average Tm of 69.46 °C. When OSM was treated with either
SMI-8H3 or SMI-8H6, OSM experienced a negative shift in TM. The average TM for
OSM treated with SMI-8H3 was calculated to be 55.12 °C, which results in an ΔTM of 14.34 °C. The average TM for OSM treated with SMI-8H6 was calculated to be 61.00 °C,
which results in a ΔTM of -8.46 °C. The larger magnitude shift observed for OSM treated
with SMI-8H3 was expected as ELISA shows the compound effectively inhibits OSM
signaling. It was hypothesized that a smaller ΔTM would be observed for OSM treated
with SMI-8H6, as it performed poorly in the ELISA experiments. These data also suggest
that both SMI-8H3 and SMI-8H6 bind to the unfolded state of OSM, which classifies
them as U-ligands.17
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Figure 3.12

SMI-8H analogs stabilize OSM

100 μM concentrations of SMI-8H3 and SMI-8H6 were added to an aqueous buffer solution containing 15 μM
OSM, 50 mM sodium phosphate, and 100 mM sodium chloride. (A) The raw fluorescence was obtained as a
function of temperature. The dashed black lines indicate the melting temperature for each specific replicate. (B)
Graph B is the first derivative of the raw fluorescence as a function of temperature (n = 3).

However, the melting curve of OSM looked irregular when compared to a
published melting curve of OSM.2 In the published OSM melting curve, there are few
inflection points rather than many observed in Figure 3.2. It has been postulated that the
multiple inflection points observed in the previous experiments suggest that OSM could
be in a dimeric form or that there could be impurities in the solution.18 Indeed, OSM has
been identified to exist in solution as a dimer, connected by a disulfide bond between
solvent exposes cysteine residues.2 To test if the multiple inflection points were
attributable to OSM dimers, Jayden Brandt (Lisa Warner lab) conducted a gel
electrophoresis experiment to separate OSM treated with and without the reducing agent
β-mercaptoethanol (BMe). If OSM exists in solution as a dimer, then treating it with a
reducing agent, such as BMe, should afford monomeric OSM by reducing the disulfide
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bonds. As seen in Figure 3.13, the OSM that was treated with the reducing agent (OSM
+BMe) produced a strong band around 21 kDa, which corresponds to the monomer of
OSM. When the reducing agent was not used (OSM -BMe), the dimer can be observed at
approximately 40 kDa. This supports the idea that the OSM used in previous DSF
experiments was several different forms of varying masses, including the original SMIconcentration experiments using SMI-10B.

Figure 3.13

OSM forms dimers.

OSM was separated by gel electrophoresis after being
treated (OSM +BMe) or not being treated (OSM +BMe).
Image courtesy of Jayden Brandt.

Another DSF experiment was run to see if the addition of a reducing agent
produced more consistent data. The samples were prepared in the same fashion as
described in the previous experiment, but Tris(2-carboxyethyl)phosphine hydrochloride
(TCEP) was introduced to all groups at a 1 mM concentration to afford monomeric OSM.
Figure 3.11 shows the DSF data obtained when SMI-8H3 and SMI-8H6 were melted with
OSM. Without any SMI added, the OSM control group (red) experienced an average TM
of 66.05 °C. When OSM was treated with either SMI-8H3 or SMI-8H6, OSM
experienced a negative shift in TM. The average TM for OSM treated with SMI-8H3 was
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calculated to be 63.08 °C, which results in a ΔTM of -2.97 °C. The average TM for OSM
treated with SMI-8H6 was calculated to be 65.01 °C, which results in a ΔTM of -1.04 °C.
The blank sample containing SYPRO, TCEP, and SMI did not fluoresce, so all
fluorescence is due to protein-SYPRO binding interactions (data not shown). The data
agree with the results from the ELISA experiments, where SMI-8H3 exhibits a stronger
binding affinity for OSM, causing a larger magnitude in a ΔTM.

Figure 3.14

SMI-8H analogs stabilize the OSM monomer

100 μM concentrations of SMI-8H3 and SMI-8H6 were added to an aqueous buffer solution containing 15 μM
OSM, 50 mM sodium phosphate, and 100 mM sodium chloride, and 1 mM TCEP. (A) The raw fluorescence was
obtained as a function of temperature. The dashed black line indicates Tm for each specific replicate. (B) Graph B
is the first derivative of the raw fluorescence as a function of temperature (n = 4).

Since previous data obtained for SMI-8H and SMI-8H3 were promising, a total of
13 SMI-8H analogs were subjected to DSF with monomeric OSM to observe trends
amongst a larger group of compounds (Figure 3.15). Unfortunately, there is no
discernable trend among the SMI-induced ΔTM values that collectively agree with the
ELISA data. For example, SMI-8H5 performed as well as SMI-8H13 in the ELISA, yet
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the SMI-8H5 barely caused a shift in melting temperature. It is possible that the lack of
trends observed in DSF is due to the difference in aqueous solubility among the SMI-8H
analogs. The only definitive conclusion that can be made so far is that the SMI-8H
analogs do bind to OSM, but their relative binding affinities have yet to be identified.

Figure 3.15

ΔTM values for SMI-8H
analogs

TM values were calculated by averaging the mean of the
four replicates for each sample. ΔTM values were
calculated by subtracting the average OSM TM value from
the experimental TM value.

3.4.4 A Cost-Benefit Analysis of Binding Assays
It is an expensive and laborious process to express and purify OSM. So, it is
necessary to perform a cost-benefit analysis of each current and prospective binding
assay. We have the expertise available to use isothermal calorimetric titrations, chemical
shift perturbation, and saturation transfer difference-nuclear magnetic resonance
experiments to measure KD values for SMIs binding to OSM. Even though isothermal
calorimetric titrations have been used to measure KD values of a structurally different
OSM-SMI analog, they are extremely sensitive to errors in concentrations, and they do
not serve as a high-throughput assay.19, 20 CSP experiments are also not ideal as the
expression of the 15N/1H OSM is expensive. Finally, STD-NMR does not serve as a highthroughput assay either as NMR-based experiments lack sensitivity in comparison to
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other analytical methods.21 However, FQ, DSF, and SPR binding experiments will be
discussed as they offer moderate to high-throughput methods of obtaining binding data.
This breakdown will only factor in the cost of specialty reagents and expensive
consumables used. The usage of protein will be discussed as one of the main determining
factors of the costs associated with the experiments, as it is the most expensive
consumable material used.
The FQ assay was the first accurate and reproducible experiment used to measure
KD values for SMIs binding to OSM. The only expensive reagent required in the FQ
assay is the reducing agent TCEP (1g/$80.50, Thermo Fisher). The most obvious benefit
is that accurate and reliable KD values can be obtained. Another advantage is that the
assays are relatively easy to run and only require protein and SMI. However, there are
some serious drawbacks. The biggest problem occurs when the SMI absorbs and/or
fluoresces near or at 350nm. In addition, the mass of OSM used to obtain a KD value for
one SMI is 66.4 μg, while DSF uses 11.8 μg. Therefore, this assay is currently the most
expensive when considering just the consumption of OSM. In theory, smaller cells could
be used that would reduce the amount needed. However, the nature of the experiment
requires mixing, which was problematic in the micro cells. Finally, FQ assays are not
high-throughput enough to assess an extensive library of compounds since an experiment
to obtain a KD value for a single SMI in triplicate requires approximately 30 minutes.
DSF experiments have been investigated as an approach to rapidly screen large
libraries of compounds. As previously discussed, in our hands, the DSF experiments
cannot be used to obtain dependable KD values based on just the ΔTM of the protein.
Given that all SMI-8H analogs that performed well by ELISA caused a ΔTM shift, the
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DSF assay may be better suited as a method to identify compounds that bind to OSM and
compounds that do not. The most obvious benefit to using DSF is that many SMIs can be
assessed at once using a 96-well plate. In addition, DSF requires less OSM per
experiment. Considering that the wells in the qPCR plate contain 20 microliters of
sample, It is possible to prepare a single experimental sample in triplicate using 11.8 μg
while still obtaining a good fluorescence signal.
SPR experiments can possibly serve as a high-throughput and accurate method of
determining binding affinities of OSM-SMIs. As seen in Figure 3.16, the experiment
begins with choosing an appropriate sensor chip (grey) to immobilize the protein of
interest (purple).22 Once the protein is successfully immobilized to the sensor chip, a
baseline reading is obtained by shining light through a high refractive index prism onto
the backside of the sensor chip and then capturing the reflected light with a detector.
When the dissolved ligand is injected across the surface of the sensor chip, the ligand can
bind to the protein adhered to the sensor chip. As a result of a binding event, the angle of
the reflected light will change, which causes a shift in the minimum intensity of the
reflected light. Most importantly, it is possible to plot SPR response vs. time to obtain
dissociation constants.
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Figure 3.16

Principles of SPR

The protein of choice is adhered to a planar sensor chip (grey), which
specifically or non-specifically binds the protein (purple). SPR response is
recorded with and without ligand flowing across the sensor chip. Upon ligand
binding, the detector measures a change in the SPR response is recorded as well
as a shift in intensity minimum of the reflected light.

Since SPR experiments have not been successfully accomplished with OSMSMIs, it is difficult to know the exact cost of determining the binding affinity of a single
SMI. An estimation of the cost of materials will have to serve as a substitute. The most
considerable benefit to using SPR is that KD values can be obtained in a high-throughput
manner, as Boise State University has a Themofinnagen Surveyor autosampler that can
hold 200 sample vials. Also, the amount of protein necessary to run an SPR binding
experiment is considerably less than both FQ and DSF assays. According to previous
experiments at Boise State University that involved OSM, only 100 μL of 20 μg/mL was
used to adhere OSM to the sensor chip surface.23 This translates to a total mass of 2.0 μg
OSM being used to prepare a single sensor chip. It is currently unknown how many
different samples can be analyzed using the same gold sensor chip. This is an important
factor, as the planar polyethylene glycol/carboxyl sensor chips (Reichert part #13206061)
previously used for OSM are currently $66.94/sensor chip. So, the economic feasibility
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of this assay will ultimately depend on the ability of the OSM to stay bound to the sensor
chip. As the instrumentation can run up to 200 samples, the limiting factor will most
likely be the ability of the protein to stay bound to the sensor chip.
In conclusion, SPR would be the best choice as it can collect gather binding data
in a high-throughput manner. However, this is assuming that OSM stays adhered to the
hydrophobic sensor chip after several wash cycles. The cost of the chips also might make
SPR expensive if used as an initial screening tool. It is imaginable that both DSF and
SPR could be used together in a simple workflow. Even though DSF does not reveal
relative binding affinities, the experiments discussed show they identify protein-ligand
binding. So, it is conceivable that extensive libraries of compounds can be screened by
DSF as it is relatively inexpensive. Once specific molecules are identified to cause shifts
in the TM of OSM, they could be further subjected to analysis by SPR to obtain direct
binding data. If both DSF and SPR are proven to give accurate and reproducible results in
future experiments, then it is possible that the FQ methodology can exist as the least
desirable option of the three binding assays.
3.5 Conclusions and Future Work
Collectively, 35 individual SMIs were synthesized according to five unique
reaction pathways and characterized using standard methods. The linear synthesis of both
SMI-8 and SMI-8S called for the planning of new synthetic routes that produced
compounds resembling SMI-8. These pathways used common medicinal chemistry
reactions, such as Pd (0) catalyzed carbon-carbon coupling, nucleophilic aromatic
substitution, amide formations, basic ester hydrolysis, heterocycle formation, and
reactions with diazonium intermediates.24 Notably, the SMI-8H analog series was the
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most amenable to functionalization as enolate formation at the α-carbon allows for
branching via an alkylation reaction, and the electrophilic carbon at the 2-position of the
thiazole can be exploited by Suzuki-Miyaura couplings and nucleophilic aromatic
substitutions. In addition, the synthesis of structurally different compounds teased out
whether specific structures were necessary for the success of SMI-8. For example, SMI-8
and SMI-8S were measured to have KD values of 5 ± 1 μM and 14 ± 3 μM, respectively.
The ELISA also shows that the dienes are not needed, as SMI-8S performed just as well
as SMI-8.
The CSP and FQ experiments support the argument that SMI-8S directly binds to
OSM, while the ELISA data show that most SMI-8 analogs inhibit OSM signaling in
T47D breast cancer cells. However, a considerable amount of the SMI-8H analogs were
within error of another in the ELISA experiments, making it difficult to establish
definitive SAR trends. The DSF experiments reveal that OSM becomes stabilized or
destabilized upon ligand binding, as evidenced by the proteins shift in TM. Unfortunately,
the results from DSF experiments of the SMI-8H analogs do not agree with the overall
trends observed in the ELISA. Therefore, it is uncertain whether this assay can be of any
practical use in ranking relative binding affinities. Finally, the perturbations of the 15N/1H
HSQC chemical shifts observed for Gln90, Arg91, and Leu92 in the CSP experiment
suggest that SMI-8S directly binds to site III of OSM and further validates the initial high
throughput virtual screening.
The most consistent interaction that the virtual docking experiments have
predicted is the hydrogen bonding interaction between the Lys166 and the thiazole(s) of
the SMI-8 analogs. It would be worthwhile to determine if replacing the bisthiazole core
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of SMI-8 and SMI-8S with a bisoxazole would prove to be beneficial. When the
bisthiazole groups were substituted with bisoxazole groups in virtual docking studies, the
binding scores were slightly lower ( -0.5 kcal/mol). Unfortunately, this is another linear
synthesis that would not afford an extensive library of compounds. However, it would
work to identify if the bisthiazole can be replaced in SMI-8 and still maintain or increase
its affinity for OSM. If this is the case, it is conceivable that a library of analogs
structurally similar to SMI-8 could be synthesized with oxazoles instead.
One of the most important questions considering the SMI-8H analogs has yet to
be answered: which enantiomer of the SMI-8H analogs is more potent? At this point in
the project, it is unknown whether the R or S enantiomer of the analogs has a greater
binding affinity. This question can be answered by taking two important steps. Step one
involves isolating the specific enantiomers of a small selection of SMI-8H compounds
via chiral chromatography and subjecting them to an adequate assay that will determine
their binding affinity. Step two involves planning a synthetic route that selectively
produces the more potent enantiomer. This can be accomplished by the use of chiral
auxiliary groups, which are temporarily incorporated into the structure to determine the
stereoselective outcome of the products.
Oxazolidinones are known to be useful chiral auxiliary groups in the context of
enolate alkylation reactions. Chiral directing groups, such as Evans’ oxazolidinones, have
proven to afford either the R or S isomer in enantiomeric excess of 98%.25 Figure 3.17
shows a proposed pathway in which the S enantiomer can be synthesized with high
selectivity. The first step of the synthesis involves installing the oxazolidinone directing
group using DCC as a peptide coupling reagent.26 Next, the formation of the enolate can
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be accomplished using lithium diisopropylamide (LDA).25 Nucleophilic attack of the
electrophile by the pi electrons is expected to occur from the si face of the prochiral
group, resulting in the formation of an S stereocenter. Finally, the oxazolidinone directing
group is removed under oxidative conditions.25 The choice to use an S or and R
oxazolidinone will depend on which enantiomer is identified to be the most potent.

Figure 3.17

Proposed enantioselective enolate alkylation

The solubility of the SMI-8 has complicated in vitro and in vivo experiments. In
addition, SwissADME has predicted that all the SMI-8H analogs have poor solubility. A
fundamental strategy used in medicinal chemistry to overcome solubility problems is to
integrate what is known as an isostere. Isosteres are simply surrogate structures that can
be used to replace functional groups that are problematic while maintaining the same
electronic features.27 Therefore, it might be advantageous to integrate certain isosteres in
these structures to increase the solubility of the compounds. The first proposed change to
the analogs includes the addition of a tetrazole isostere as a replacement for carboxylic
acid functional groups.28 It is hypothesized that the introduction of a tetrazole to the SMI8H analog structure will improve solubility in aqueous media, as Lassalass and
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coworkers determined that tetrazole derivatives participate in stronger hydrogen-bond
interactions than their corresponding amino acids.27
Virtual ligand docking experiments have guided the synthesis of the SMI-8
analogs, but a more robust method is needed. Therefore, it is proposed that a structureactivity relationship be created to help guide future students working on the project. This
can be accomplished with a three-dimensional quantitative structural activity relationship
(3D QSAR) model with as little as twenty compounds.29 Roger Vuong (Don Warner lab)
has developed a 3DQSAR model of SMI-26, as seen in Figure 3.18. To create the contour
map seen in panel B, twenty-four SMI-26 analogs were aligned using Open3DALIGN
and imported Into 3DQSAR30 along with their respective KD values. These data were
then used to visualize a contour map in PyMOL.

Figure 3.18

A 3DQSAR model of SMI-26

(A) The SMI-26 scaffold is a quinoline core in which the R1, R2, and R3 groups have been appended with different
groups. (B) A contour map of SMI-26 was generated using 3DQSAR to observe favorable interactions.

In panel B, several trends can be identified. For example, favored groups at the R1
substitution site include phenyl groups with small, negatively charged substituents at the
ortho position, while positively charged groups seem to be favored at the meta position.
In respect to the R2 substitution site, it is overwhelmingly clear that steric bulk is
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preferred at the bottom portion of the quinoline ring. The substituent favorability at the
R3 substitution site remains ambiguous. Creating a model as described will undoubtedly
help guide future students in their goals of optimizing SMI-8 analogs.
The inability of the SMI-8H analogs to be subjected to FQ assays has been a
serious obstacle in determining the direct binding affinities to OSM. So, the next logical
step in the SMI-8 project is to develop a high-throughput binding assay to assess the
compound’s affinities towards OSM. As previously discussed, it is conceivable that SPR
can be used to determine direct binding affinities of the SMI-8H analogs. This approach
is promising, as other research groups at Boise State University have obtained binding
affinities of extracellular matrix and neutralizing OSM antibodies towards OSM using a
published approach.31 Not only will this allow reliable SAR trends of the SMI-8H
analogs to be identified, but it will also greatly expand the scope of the SMI project as a
whole.

105
3.6 Chapter Three References
1.
Tanaka, M.; Miyajima, A., Oncostatin M, a multifunctional cytokine. Rev Physiol
Biochem Pharmacol 2003, 149, 39-52.
2.
Mass, O. A.; Tuccinardi, J.; Woodbury, L.; Wolf, C. L.; Grantham, B.;
Holdaway, K.; Pu, X.; King, M. D.; Warner, D. L.; Jorcyk, C. L.; Warner, L. R.,
Bioactive recombinant human oncostatin M for NMR-based screening in drug discovery.
Scientific Reports 2021, 11 (1), 16174.
3.
Mahmood, T.; Yang, P. C., Western blot: technique, theory, and trouble shooting.
N Am J Med Sci 2012, 4 (9), 429-34.
4.
Dey, G.; Radhakrishnan, A.; Syed, N.; Thomas, J. K.; Nadig, A.; Srikumar, K.;
Mathur, P. P.; Pandey, A.; Lin, S.-K.; Raju, R.; Prasad, T. S. K., Signaling network of
Oncostatin M pathway. J Cell Commun Signal 2013, 7 (2), 103-108.
5.
Jarmoskaite, I.; AlSadhan, I.; Vaidyanathan, P. P.; Herschlag, D., How to
measure and evaluate binding affinities. Elife 2020, 9, e57264.
6.
Charlier, H. A., Jr.; Plapp, B. V., Kinetic cooperativity of human liver alcohol
dehydrogenase gamma(2). J Biol Chem 2000, 275 (16), 11569-75.
7.
Yammine, A.; Gao, J.; Kwan, A. H., Tryptophan Fluorescence Quenching
Assays for Measuring Protein-ligand Binding Affinities: Principles and a Practical Guide.
Bio Protoc 2019, 9 (11), e3253.
8.
Williamson, M. P., Using chemical shift perturbation to characterise ligand
binding. Prog Nucl Magn Reson Spectrosc 2013, 73, 1-16.
9.
Hoffman, R. C.; Moy, F. J.; Price, V.; Richardson, J.; Kaubisch, D.; Frieden,
E. A.; Krakover, J. D.; Castner, B. J.; King, J.; March, C. J.; Powers, R., Resonance
assignments for Oncostatin M, a 24-kDa alpha-helical protein. J Biomol NMR 1996, 7
(4), 273-82.
10.
Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D.
M.; Meng, E. C.; Ferrin, T. E., UCSF Chimera--a visualization system for exploratory
research and analysis. J Comput Chem 2004, 25 (13), 1605-12.
11.
Lee, W.; Tonelli, M.; Markley, J. L., NMRFAM-SPARKY: enhanced software
for biomolecular NMR spectroscopy. Bioinformatics 2015, 31 (8), 1325-7.
12.
Ulrich, E. L.; Akutsu, H.; Doreleijers, J. F.; Harano, Y.; Ioannidis, Y. E.; Lin,
J.; Livny, M.; Mading, S.; Maziuk, D.; Miller, Z.; Nakatani, E.; Schulte, C. F.;
Tolmie, D. E.; Kent Wenger, R.; Yao, H.; Markley, J. L., BioMagResBank. Nucleic
Acids Research 2007, 36 (suppl_1), D402-D408.
13.
Zbacnik, T. J.; Holcomb, R. E.; Katayama, D. S.; Murphy, B. M.; Payne, R.
W.; Coccaro, R. C.; Evans, G. J.; Matsuura, J. E.; Henry, C. S.; Manning, M. C., Role
of Buffers in Protein Formulations. J Pharm Sci 2017, 106 (3), 713-733.
14.
Niesen, F. H.; Berglund, H.; Vedadi, M., The use of differential scanning
fluorimetry to detect ligand interactions that promote protein stability. Nature Protocols
2007, 2 (9), 2212-2221.
15.
Holdgate, G. A.; Ward, W. H., Measurements of binding thermodynamics in drug
discovery. Drug Discov Today 2005, 10 (22), 1543-50.
16.
Schellman, J. A., Temperature, stability, and the hydrophobic interaction. Biophys
J 1997, 73 (6), 2960-4.

106
17.
Cimmperman, P.; Baranauskiene, L.; Jachimoviciūte, S.; Jachno, J.; Torresan,
J.; Michailoviene, V.; Matuliene, J.; Sereikaite, J.; Bumelis, V.; Matulis, D., A
quantitative model of thermal stabilization and destabilization of proteins by ligands.
Biophysical journal 2008, 95 (7), 3222-3231.
18.
Warner, L., Boise State University, Boise, ID. Personal communication, 2021.
19.
Dutta, A. K.; Rösgen, J.; Rajarathnam, K., Using isothermal titration calorimetry
to determine thermodynamic parameters of protein-glycosaminoglycan interactions.
Methods Mol Biol 2015, 1229, 315-24.
20.
Torres, F. E.; Recht, M. I.; Coyle, J. E.; Bruce, R. H.; Williams, G., Higher
throughput calorimetry: opportunities, approaches and challenges. Curr Opin Struct Biol
2010, 20 (5), 598-605.
21.
Ardenkjaer-Larsen, J.-H.; Boebinger, G. S.; Comment, A.; Duckett, S.; Edison,
A. S.; Engelke, F.; Griesinger, C.; Griffin, R. G.; Hilty, C.; Maeda, H.; Parigi, G.;
Prisner, T.; Ravera, E.; van Bentum, J.; Vega, S.; Webb, A.; Luchinat, C.; Schwalbe,
H.; Frydman, L., Facing and Overcoming Sensitivity Challenges in Biomolecular NMR
Spectroscopy. Angewandte Chemie (International ed. in English) 2015, 54 (32), 91629185.
22.
Tang, Y.; Zeng, X.; Liang, J., Surface Plasmon Resonance: An Introduction to a
Surface Spectroscopy Technique. J Chem Educ 2010, 87 (7), 742-746.
23.
Ryan, R. E.; Martin, B.; Mellor, L.; Jacob, R. B.; Tawara, K.; McDougal, O.
M.; Oxford, J. T.; Jorcyk, C. L., Oncostatin M binds to extracellular matrix in a bioactive
conformation: implications for inflammation and metastasis. Cytokine 2015, 72 (1), 7185.
24.
Brown, D. G.; Boström, J., Analysis of Past and Present Synthetic Methodologies
on Medicinal Chemistry: Where Have All the New Reactions Gone? Journal of
Medicinal Chemistry 2016, 59 (10), 4443-4458.
25.
Heravi, M. M.; Zadsirjan, V.; Farajpour, B., Applications of oxazolidinones as
chiral auxiliaries in the asymmetric alkylation reaction applied to total synthesis. RSC
advances 2016, 6 (36), 30498-30551.
26.
Shen, X. Method for preparing intermediate of PARP-1 (poly(adenosine
diphosphate-ribose) polymerase-1) inhibitor Niraparib. 2018.
27.
Lassalas, P.; Gay, B.; Lasfargeas, C.; James, M. J.; Tran, V.; Vijayendran, K.
G.; Brunden, K. R.; Kozlowski, M. C.; Thomas, C. J.; Smith III, A. B., Structure
property relationships of carboxylic acid isosteres. Journal of medicinal chemistry 2016,
59 (7), 3183-3203.
28.
Ballatore, C.; Huryn, D. M.; Smith, A. B., 3rd, Carboxylic acid (bio)isosteres in
drug design. ChemMedChem 2013, 8 (3), 385-95.
29.
McKinney, J. D.; Richard, A.; Waller, C.; Newman, M. C.; Gerberick, F., The
Practice of Structure Activity Relationships (SAR) in Toxicology. Toxicological Sciences
2000, 56 (1), 8-17.
30.
Tosco, P.; Balle, T., Open3DQSAR: a new open-source software aimed at highthroughput chemometric analysis of molecular interaction fields. Journal of molecular
modeling 2011, 17 (1), 201-208.
31.
Jorcyk, C. L.; Holzer, R. G.; Ryan, R. E., Oncostatin M induces cell detachment
and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine
2006, 33 (6), 323-36.

107

APPENDIX A
Materials and Methods
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Biological Based Evaluations
General procedure for enzyme-linked immunosorbent assays: Inhibition of pSTAT3
expression was determined by an ELISA using T47D human breast cancer cell lines. The
breast cancer cells were serum-starved for 4 hours to halt the growth and further
development of the cell. The SMI-8 analogs (10 μM in DMSO) were then incubated with
recombinant hOSM at a 10 ng/ml concentration in a serum-free RPMI-1640 growth
medium at 37 °C and 5% CO2 for 1 hour. Following the incubation period, the SMI-8
analogs and recombinant hOSM mixture stimulated the serum-starved cells for 30
minutes. Afterward, the cells were then lysed using a 1x PathScan Sandwich ELISA lysis
buffer (CST #7018S) for 15 minutes. After lysis was completed, the cell lysates were
collected and stored at -20 °C. The collected lysates were warmed to room temperature,
then analyzed for levels of pSTAT3 expression using a human/mouse DuoSet® IC
ELISA sandwich ELISA antibody pair kit (R&D Systems). This was accomplished by
transferring the lysates to a 96 well plate and measuring with absorbance at 450 nm.
Next, pSTAT3 levels were quantified by relative comparison to OSM-induced levels of
pSTAT3 expression.
General Procedure for fluorescence quenching assays: SMIs were prepared as a 1.875
mM DMSO solution by diluting a previously prepared 10 mM stock solution in DMSO.
In four separate polymethylmethacrylate cuvettes was added 750 μL of a stock solution
containing 1.0 μM recombinant hOSM, 0.1 mM tris(2-carboxyethyl)phosphine (TCEP),
50 mM sodium phosphate, and 100 mM NaCl (pH = 6.6). Three of the cuvettes were
titrated with 0-100 μM SMI, while the fourth cuvette was titrated with DMSO to serve as
a blank. A total of 11 titration points are collected, which includes the initial excitation of
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OSM without adding any SMI. At no point does the DMSO exceed 5% of the total
solution (v/v). The wavelength emission of the fluorimeter was set to 280 nm, while the
fluorescence intensity of OSM was observed at 350 nm. The slit width was set to 4nm,
and the photomultiplier voltage was set to 700V. Each titration point obtained from the
experimental group was normalized to the fluorescence intensity of the OSM control
group in the absence of a small molecule. The samples run in triplicate values are then
averaged to yield a single value for each titration point. These averaged values at each
titration point are then plotted against the concentration of SMI delivered and fit to a
𝑓𝑓

modified Stern-Volmer function, � � = �
𝑓𝑓𝑜𝑜

𝑓𝑓1

1−

[𝑋𝑋]
𝐾𝐾𝑑𝑑

𝑓𝑓

� + (1 − 𝑓𝑓1 ), where � � is the measured
𝑓𝑓𝑜𝑜

fluorescence signal of the sample containing SMI divided by the fluorescence signal of

the DMSO blank, 𝑓𝑓1 is the fraction of fluorescence quenched, [X] is the concentration of

SMI, and KD is the binding affinity of the SMI towards OSM.1 KD values were calculated
from the fitting routine, and the errors for each titration point were reported as the
standard error of the fit with a symmetrical 95% confidence interval. The raw data were
analyzed using Microsoft Excel, and the curve fitting analysis was accomplished in
GraphPad Prism 8.2
General Procedure for Differential Scanning Fluorimetry Assays: The assay buffer was
prepared as a DI H2O-based solution containing 100 mM NaCl and 50 mM NaPi (pH =
6.8). All samples were prepared in this buffer. Before diluting the stock solution of
SYPRO orange to a manageable volume, the small tube containing the 5,000X stock
concentrated solution was brought to room temperature and spun down on a mini
centrifuge for 10 seconds to ensure homogeneity. The concentration of OSM was kept
constant, as well as the concentrations of ligands used. In order to prepare samples in
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triplicate, control groups and experimental groups were all prepared in 1.5 mL Eppendorf
tubes with a final volume of 100 μL, where the final target concentration of OSM was 15
μL, the final DMSO concentration did not exceed 2% (v/v), the final SYPRO Orange
concentration was 10X, the final SMI concentration in the Eppendorf tube was 100 μM,
and the final concentration of TCEP was 1 mM. The TCEP was added to the samples last
and allowed to sit at room temperature for 30 minutes. Once the 150 μL stock solutions
were prepared in the Eppendorf tubes, 4 x 20 μL aliquots were pipetted from the 150 μL
Eppendorf solutions into a 96 well qPCR plate to run both control and experimental
groups in quadruplicate. A sealable plastic covering was placed atop the 96 well plate and
centrifuged at 500 x g for 1 minute to get rid of any air bubbles in the wells. The data
were collected on a QuantStudio3 qPCR instrument (Applied Biosystems). The samples
were equilibrated at 25 °C for 2 minutes before being gradually heated up to 99 °C,
where fluorescence measurements were recorded at intervals of approximately 0.05 °C
increments. The data were analyzed using Protein Thermal Shift software (ThermoFisher
Scientific). The TM values were calculated as an average value for the replicates and
identified as the maximum y-value of the first derivative of the raw fluorescence data vs.
temperature.
General Procedure for chemical shift perturbation experiments: The HSQC sample was
prepared as a 600μL protein/buffer solution containing 100 μM 15N/1H recombinant
human OSM, 50 mM sodium phosphate, 100 mM sodium chloride, and 5% D2O. (pH =
6.6). 5 mM NMR tubes were used. The titration series was performed by pipetting 1.5,
3.0, or 6.0 μL aliquots of a 4.2 mM SMI-8S solution prepared in DMSO into the
protein/buffer solution. Overall, 10 titration points were collected, which correspond to
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SMI-8S concentrations of 0-180.9 μM. Spectra were obtained at 298K on a Bruker
AVANCE III 600 MHz spectrometer equipped with a 5 mm TCI cryoprobe with z-axis
gradients. HSQC spectra were obtained with the hsqcfpf3gpphwg preset Bruker sequence.
The resulting spectra were processed using Topspin 3.2.
Computational Modeling
General procedure for computational docking studies: The virtual docking studies
referenced in this document were performed using AutoDock Vina 4.2 using the ff14SB
force feild.3, 4 The crystal structure of hOSM was uploaded to University of California
San-Francisco Chimera 1.14 using the protein data bank (PDB) code 1EVS. The protein
was then prepared for docking interactions by using the “Dock Prep” action. Next, the
small molecule ligand under investigation was drawn in ChemDraw 16.0 and imported
into Chimera as a SMILES code. Both small molecule minimization and addition of net
charges were accomplished by using the Antechamber module, which uses the default
ff14SB force field—opening the “AutoDock Vina” tab located in the tools section
allowed small molecule docking parameters to be set. The center docking coordinates
were assigned to (10, 35, 25), and the size coordinates were assigned to (30,30,30). No
further manipulation of the molecule and/or protein was done after the AutoDock Vina
function was run.
Instrumental Analysis
General information regarding methods of Instrumentation: Both 1H and 13C
spectroscopic data were obtained using a Bruker AVANCE III 600 MHz spectrometer
equipped with a 5 mm TCI cryoprobe with z-axis gradients or a Bruker AVANCE III 300
MHz spectrometer. All spectra of intermediates and final compounds were obtained at
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298K using reagent grade CDCl3 (99.9% D atom) or DMSO-d6 (99.9% D atom). Both
deuterated reagents were stored under 3Å molecular sieves. In addition to the DMSO-d6
being stored over molecular sieves, it was also stored in a container filled with calcium
chloride. The CDCl3 residual CHCl3 signal at δ(H) = 7.26 ppm and the central resonance
signal of the CDCl3 triplet signal at δ(C) = 77.20 ppm were used to reference 1H and 13C,
respectfully. The residual DMSO-H6 signal at δ(H) = 2.50 ppm and the residual signal at
δ(C) = 39.52 ppm were used to reference 1H and 13C, respectively. The HNMR data were
recorded as follows: chemical shift (δ), multiplicity, coupling constant(s) J (Hz), relative
integral, where the multiplicity is denoted as s = singlet; d = doublet; t = triplet; q =
quartet; hept = heptet; sept = septet; m = multiplet or a combination of multiplets. 5mm
NMR tubes were used for sample preparation with either deuterated solvent previously
discussed. The original free induction decay data from spectra were originally
transformed and observed using Bruker Topspin. Afterward, the data were plotted and
analyzed MestReNova version 14.2.1. The reverse-phase high-pressure liquid
chromatography (HPLC) analyses were accomplished using an Agilent 1100 series
HPLC equipped with a Phenomenex Synergi Fusion C18 column. The mobile phase
consisted of a 95:5 mixture containing 95 parts acetonitrile and 5 parts 0.1% aqueous
trifluoroacetic acid. The instrument was also equipped with a diode array detector in
order to determine specific absorbance. The area under the peaks was automatically
integrated by the software. Samples were sent to the Biological Research Center at Boise
State University for high-resolution mass spectroscopy (HRMS). Mass spectra were
obtained in positive ion mode using a Bruker Daltonics MaXis-Time of flight mass
spectrometer. Melting points for all final compounds were observed using a Vernier Melt
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Station MLT-BTA as uncorrected results. DSF experiments were run using a
QuantStudio3 qPCR instrument, and the data were analyzed using Protein Thermal Shift
software.
Synthetic Chemistry
General information regarding glassware and reagents: The reagents used in the
synthesis were purchased directly from chemical suppliers as the highest purity possible
unless otherwise noted. All glassware used was either oven-dried, or flame dried using a
propane torch. After being flame dried or oven-dried, the glassware was cooled under an
inert N2 atmosphere using direct in and out gas lines. All reactions were stirred by a
magnetic stir bar placed in the reaction vessels. Any solvents used in the syntheses were
either distilled to be anhydrous or purchased as anhydrous and kept under 3Å molecular
sieves in round bottom flasks with Teflon caps. The reactions were monitored by glassbacked TLC plates coated with 250 mm silica gel. Ultraviolet light active compounds
were visualized on the TLC plate using a 240 nm light. KMnO4, ninhydrin stain, and
curcumin stains were all used in conjunction with subsequent heating in order to identify
the consumption and formation of compounds with specific functional groups. Unless
otherwise noted, all reactions were either performed under inert Argon or N2 gas
atmosphere. Flash column chromatography was used in order to separate compounds. All
columns were packed as a slurry using 60Å, 230-400 mesh silica gel.
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General procedure for HATU mediated amidations: To a round bottom flask was added
1.0 eq. of carboxylic acid starting material, which was dissolved in dimethylformamide
(~0.2M). Once dissolved, 1.0 eq. of HATU [(1-[Bis(dimethylamino)methylene]-1H1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate] was transferred to the
reaction flask and dissolved with continuous magnetic stirring. After the HATU was
dissolved, the flask was capped with a rubber septum and purged with N2 gas. 1.3 eq. of
N,N-Diisopropylethylamine (DIPEA) was added via syringe, and the reaction solution
was allowed to stir for 1.0 hours at room temperature under N2 gas. After stirring at room
temperature, 1.0 eq. of m-carboxyaniline was added to the flask, and the reaction mixture
was heated to 80 °C for 3 hours under N2. The flask was cooled to room temperature,
then the contents were dissolved in ethyl acetate (~25 mL), washed with an aqueous 1N
HCl solution (2 x 15 mL), aqueous 1N NaOH solution (2 x 15 mL), and then washed
with DI H2O (5 x 15 mL). The organic layer was dried over anhydrous MgSO4 and
filtered through a fritted glass funnel. The filtered organic layer was concentrated under
reduced pressure to afford a white/yellow solid. The solid was then further purified by
flash column chromatography. The appropriate fractions were collected and concentrated
under reduced pressure.
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General procedure for BOP mediated amidations: To a flask was added 1 eq. of
bisthiazole, 2.4 eq. of substituted aniline, and 2.4 eq. BOP [benzotriazol-1yloxytris(dimethylamino)phosphonium hexafluorophosphate)]. Dimethylformamide was
then added to the mixture of reagents in the flask (~0.05M). The flask was capped with a
rubber septum and purged with N2 atmosphere. Once the solids were dissolved, 3 eq. of
N,N-Diisopropylethylamine (DIPEA) were added via syringe. The reaction mixture was
stirred for 14 hours under N2 gas. After the 14-hour mark, a white precipitate was
observed. The white solid was filtered out using vacuum filtration. The white solid was
washed on the Hirsch funnel with ~25 mL of DI H2O. The solids were transferred to
small vials and triturated with dichloromethane until a fine suspension was achieved. The
white suspension was then filtered on a Hirsch funnel to dry. Trace dichloromethane was
removed by subjecting the solids to vacuum overnight.
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General procedure for saponification of esters: 1 eq. of the ethyl ester was added to an
appropriately sized round bottom flask and dissolved in ethanol (~0.1M). 2 eq. of lithium
hydroxide. To increase the solubility of the LiOH, DI H2O was added to the ethanol so
that the reaction mixture was 90 parts EtOH and 10 parts H2O (v:v). A Liebig condenser
was attached to the round bottom flask joint and capped with a rubber septum. The
apparatus was flushed with N2 gas and heated to 50 °C for 3 hours, or until the reaction
was observed to be complete by TLC. Once complete, the flask was cooled to room
temperature, and the solvent was removed under reduced pressure and light heating in a
water bath. The resulting solid or oil was taken up into ~20 mL of H2O and acidified to
pH 2-3, where the free acid precipitated out of water. The solid was then filtered by
vacuum filtration to afford the saponified product.
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General procedure for Pd catalyzed carbon-carbon coupling: To a round bottom flask
was added 1 eq. aryl bromide material, 1.5 eq. of appropriate boronic acid, and 2 eq. of
K3PO4. Dioxane was then added to the flask via syringe (~0.2M). DI H2O was added to
the flask afterward so that the reaction mixture was 90 parts dioxane and 10 parts H2O
(v:v). A Liebig condenser was placed on top of the round bottom flask and the top of the
Liebig condenser was capped with a rubber septum. The reflux apparatus was purged
with N2 gas for ~3 minutes. Once purged, palladium triphenylphosphine was weighed out
in the open air as quickly as possible and put into the flask. The apparatus was purged
again with N2 and then heated to 100 °C for a minimum duration of 15 hours. During the
heating, the contents of the reaction apparatus were kept under static N2. After 15 hours,
the round bottom flask was allowed to cool to room temperature, and the dioxane solvent
was removed by reduced pressure and a hot water bath. The crude organic matter was
taken up into dichloromethane (~20 mL), washed with DI H2O (5 x 10 mL), an aqueous
1N solution of NaOH (~15 mL), and saturated brine solution (~10 mL). The organic layer
was dried with anhydrous MgSO4 and vacuum filtered through a sintered glass funnel.
The organic layer was reduced under negative pressure to produce a black oil. The oil
was then purified by flash column chromatography, and the appropriate fractions were
collected.
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General procedure for nucleophilic aromatic substitutions: To a round bottom flask
was added 1 eq. of the aryl bromide starting material and 1 eq. of substituted aniline. The
contents of the flask were then dissolved in dioxane (~0.2M). A Liebig condenser was
attached to the round bottom in preparation for reflux. The top of the Liebig condenser
was capped with a rubber septum and purged with N2, and the reaction mixture was
refluxed for 2 days under a static pressure of N2 gas. After 48 hours, the starting material
was observed to still be present. 3 more eq. of the substituted aniline was added to the
reaction flask and refluxed for another 3 days under a static pressure of N2 gas. Once the
flask was cooled to room temperature, the contents were reduced under negative pressure
and a heated water bath. The resulting oil was taken up in ~15 mL of dichloromethane,
washed with DI H2O (5 x 15 mL), 15 mL of an aqueous solution of 1N HCl, and 15 mL
of an aqueous 1N solution of NaOH. The solids obtained from the nucleophilic aromatic
substitution were either triturated, recrystallized, or separated by column chromatography
to produce solids.
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General Procedure for the Hantzsch thiazole synthesis: To an appropriately sized round
bottom flask were added 2.1 eq. of 4-bromo ethyl acetoacetate and 1.0 eq. of
dithiooxamide. Ethanol was used to dissolve the contents of the flask (~0.30 M). A
Liebig condenser was attached to the round bottom flask to construct a reflux apparatus.
The top of the reflux condenser was capped with a rubber septum, and the apparatus was
purged with N2 gas. The reaction was refluxed at 80 °C for a minimum of 14 hours. After
reflux, the round bottom flask was cooled to room temperature. The ethanol in the flask
was reduced by negative pressure to yield a flaky yellow solid. The solid was taken up in
~25 mL dichloromethane. The organic layer was washed with 15 mL 1N aqueous
solution HCl, and 15 mL 1N aqueous solution NaOH, and ~20 mL DI H2O. The organic
layer was then dried with MgSO4 and vacuum filtered to produce a dark black liquid in
dichloromethane. The dichloromethane was removed under reduced pressure to afford a
brown/tan flaky solid. The brown/tan solid was then recrystallized in an EtOH/hexanes
solvent system and vacuum filtered to afford thin golden-colored crystals.
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SMI-8
(2Z/E,2'Z,4E,4'E)-2,2'-([2,2'-bithiazole]-4,4'-diyl)bis(5-phenylpenta-2,4-dienoic acid)
Prepared according to the general saponification procedure to afford a bright yellow solid
(54% yield). 1H NMR (600 MHz, DMSO) δ 13.09 (s, 2H), 8.12 (d, J = 12.3 Hz, 1H),
7.98 (d, J = 7.9 Hz, 1H), 7.92 – 7.76 (m, 1H), 7.77 – 7.60 (m, 3H), 7.57 (dd, J = 7.8, 5.7
Hz, 4H), 7.46 – 7.38 (m, 4H), 7.37 – 7.30 (m, 2H), 7.24 (dd, J = 15.5, 5.2 Hz, 1H), 7.18
(dd, J = 15.2, 6.5 Hz, 1H). 13C NMR (151 MHz, DMSO) δ 119.97, 120.09, 123.35,
123.50, 124.29, 124.41, 125.10, 125.36, 126.54, 126.68, 127.15, 127.41, 128.96, 129.02,
129.06, 129.25, 136.26, 136.39, 136.86, 136.98, 140.01, 141.14, 141.80, 150.42, 152.27,
158.93, 159.31, 159.79, 160.16, 167.59, 167.62, 167.73, 167.75. HPLC: TR = 4.352 min,
peak area = 92.3%. MP: 266.5-270.8 °C. HRMS m/z: [M + Na]+ Calcd. for
C28H20N2O4S2 535.0757; Found 535.0759, Error 0.4 ppm.

SMI-8S
2,2'-([2,2'-bithiazole]-4,4'-diyl)bis(5-phenylpentanoic acid)
Prepared to the general saponification procedure to afford a bright white solid (38%
yield). 1H NMR (300 MHz, DMSO) δ 12.56 (s, 2H), 7.65 (s, 2H), 7.26 (t, J = 7.4 Hz,
4H), 7.16 (d, J = 7.2 Hz, 6H), 3.87 (t, J = 7.4 Hz, 2H), 2.60 (t, J = 7.6 Hz, 4H), 1.93 (ddt,
J = 29.8, 14.2, 5.7 Hz, 4H), 1.73 – 1.39 (m, 4H).13C NMR (75 MHz, DMSO) δ 29.23,
31.33, 35.18, 47.54, 118.85, 126.16, 128.72, 142.31, 156.01, 160.37, 173.92. HPLC: TR =
4.377 min, peak area = 98.1%. MP: 188.8-191.3 °C. HRMS m/z: [M + H]+ Calcd. for
C28H28N2O4S2 521.1563; Found 521.1556, Error -1.4 ppm.
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SMI-8S3
5-phenyl-2-(thiazol-4-yl)pentanoic acid
Prepared to the general saponification procedure to afford a bright white solid (58%
yield). 1H NMR (600 MHz, CDCl3) δ 12.07 (s, 1H), 8.85 (d, J = 2.0 Hz, 1H), 7.26 (t, J =
7.5 Hz, 2H), 7.22 – 7.10 (m, 4H), 4.01 (t, J = 7.5 Hz, 1H), 2.69 – 2.58 (m, 2H), 2.16
(dddd, J = 13.1, 10.4, 7.4, 5.5 Hz, 1H), 2.07 – 1.97 (m, 1H), 1.78 – 1.53 (m, 2H). 13C
NMR (151 MHz, CDCl3) δ 29.06, 32.04, 35.52, 47.55, 115.47, 125.89, 128.38, 128.42,
141.85, 153.45, 153.88, 176.97. HPLC: TR = 5.540 min, peak area = 47.6%. MP: 83.284.0 °C. HRMS m/z: [M + H]+ Calcd. for C14H15NO2S 262.0896; Found 262.0899, Error
1.0 ppm.

SMI-8A4
3,3'-((2,2'-([2,2'-bithiazole]-4,4'-diyl)bis(acetyl))bis(azanediyl))dibenzoic acid
Prepared to the general saponification procedure to afford a bright yellow solid (46%
yield). 1H NMR (600 MHz, DMSO) δ 12.91 (s, 2H), 10.42 (s, 2H), 8.26 (s, 2H), 7.84 (d,
J = 8.3 Hz, 2H), 7.68 (s, 2H), 7.63 (d, J = 7.7 Hz, 2H), 7.44 (t, J = 7.9 Hz, 2H), 3.93 (s,
4H). 13C NMR (151 MHz, DMSO) δ 119.35, 119.88, 123.21, 124.11, 128.99, 131.30,
139.22, 151.48, 159.85, 167.05, 167.72. HPLC: TR = 3.540 min, peak area = 96.7%. MP:
>303.6 °C. HRMS m/z: [M + Na]+ Calcd. for C24H18N4O6S2 545.0560; Found 545.0582,
Error 4.0 ppm.
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SMI-8A4Cl
2,2'-([2,2'-bithiazole]-4,4'-diyl)bis(N-(4-chlorophenyl)acetamide)
Prepared according to the general BOP mediated amidation procedure to afford a bright
white solid (46% yield). 1H NMR (300 MHz, DMSO) δ 10.40 (s, 2H), 7.81 – 7.55 (m,
6H), 7.48 – 7.28 (m, 4H), 3.91 (s, 4H). 13C NMR (151 MHz, DMSO) δ 119.51, 120.69,
126.91, 128.73, 138.05, 151.53, 159.91, 167.71 . HPLC: TR = 4.002 min, peak area =
96.2%. MP: > 303.6 °C. HRMS m/z: [M + H]+ Calcd. for C22H16Cl2N4O2S2 503.0165;
Found 503.0178, Error 2.6 ppm.

SMI-8A4OMe
2,2'-([2,2'-bithiazole]-4,4'-diyl)bis(N-(4-methoxyphenyl)acetamide)
Prepared according to the general BOP mediated amidation procedure to afford a bright
white solid (44% yield). 1H NMR (600 MHz, DMSO) δ 10.07 (s, 2H), 7.65 (s, 2H), 7.55
– 7.49 (m, 4H), 6.91 – 6.85 (m, 4H), 3.86 (s, 4H), 3.72 (s, 6H). 13C NMR (75 MHz,
DMSO) δ 55.61, 114.34, 119.70, 121.13, 132.70, 152.35, 155.71, 160.31, 167.41. HPLC:
TR = 3.763 min, peak area = 97.6%. MP: > 303.6 °C. HRMS m/z: [M + H]+ Calcd. for
C24H22N4O4S2 495.115; Found 495.1178, Error 4.6 ppm.
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SMI-8M1
3-(2-(4-isobutylphenyl)thiazole-4-carboxamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (70%
yield). 1H NMR (600 MHz, DMSO) δ 13.18 (s, 1H), 10.42 (s, 1H), 8.47 (d, J = 9.8 Hz,
2H), 8.12 – 8.05 (m, 3H), 7.71 (dt, J = 7.7, 1.3 Hz, 1H), 7.49 (t, J = 7.9 Hz, 1H), 7.37 –
7.33 (m, 2H), 2.54 (d, J = 7.2 Hz, 2H), 1.89 (dt, J = 13.5, 6.8 Hz, 1H), 0.89 (d, J = 6.6
Hz, 6H). 13C NMR (151 MHz, DMSO) δ 22.55, 30.05, 44.77, 121.80, 125.10, 125.19,
125.61, 127.01, 129.34, 130.18, 130.54, 131.71, 139.12, 144.89, 150.51, 159.70, 167.64,
167.95. HPLC: TR = 4..594 min, peak area = 98.6%. MP: 224.3-225.7 °C. HRMS m/z:
[M + H]+ Calcd. for C21H20N2O3S 381.1267; Found 381.1254, Error -3.4 ppm.

SMI-8M2
3-(2-(3-chlorophenyl)thiazole-4-carboxamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (53%
yield). 1H NMR (600 MHz, DMSO) δ 13.02 (s, 1H), 10.49 (s, 1H), 8.55 (s, 1H), 8.50 (t, J
= 1.9 Hz, 1H), 8.35 (t, J = 1.8 Hz, 1H), 8.16 – 8.11 (m, 1H), 8.07 (dt, J = 7.5, 1.5 Hz,
1H), 7.72 (dt, J = 7.8, 1.3 Hz, 1H), 7.64 – 7.56 (m, 2H), 7.51 (t, J = 7.9 Hz, 1H). 13C
NMR (151 MHz, DMSO) δ 121.51, 124.74, 124.81, 125.49, 126.03, 126.33, 128.84,
130.54, 131.14, 131.40, 134.12, 134.24, 138.57, 150.22, 159.06, 165.56, 167.18. HPLC:
TR = 4.151 min, peak area = 95.1%. MP: 269.5-272.3 °C. HRMS m/z: [M + H]+ Calcd.
for C17H11ClN2O3S 359.0252; Found 359.0239, Error -3.5 ppm.
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SMI-8M3
3-(2-(4-chlorophenyl)thiazole-4-carboxamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (81%
yield). 1H NMR (300 MHz, DMSO) δ 12.98 (s, 1H), 10.47 (s, 1H), 8.52 (s, 1H), 8.49 (t, J
= 1.9 Hz, 1H), 8.23 – 8.17 (m, 2H), 8.13 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H), 7.72 (dt, J = 7.9,
1.3 Hz, 1H), 7.69 – 7.54 (m, 2H), 7.50 (t, J = 7.9 Hz, 1H). 13C NMR (151 MHz, DMSO)
δ 121.44, 124.68, 124.83, 126.10, 128.48, 128.95, 129.33, 131.27, 131.39, 135.52,
138.67, 150.26, 159.16, 166.04, 167.27. HPLC: TR = 4.191 min, peak area = 90.6%. MP:
259.6-274.1 °C. HRMS m/z: [M + H]+ Calcd. for C17H11ClN2O3S 359.0252; Found
359.0247, Error -1.3 ppm.

SMI-8M4
3-(2-phenylthiazole-4-carboxamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (76%
yield). 1H NMR (600 MHz, DMSO) δ 12.61 (s, 1H), 10.45 (s, 2H), 8.51 (s, 2H), 8.25 –
8.14 (m, 2H), 8.15 – 8.04 (m, 1H), 7.72 (d, J = 7.7 Hz, 1H), 7.65 – 7.51 (m, 2H), 7.50 (t,
J = 7.9 Hz, 1H). 13C NMR (151 MHz, DMSO) δ 121.48, 124.58, 124.85, 125.66, 126.77,
128.89, 129.30, 130.97, 131.81, 132.43, 138.65, 150.26, 159.27, 167.43, 167.70. HPLC:
TR = 4.058 min, peak area = 96.9%. MP: 242.1-245.8 °C. HRMS m/z: [M + H]+ Calcd.
for C17H12N2O3S 325.0641; Found 325.0630, Error -3.5 ppm.
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SMI-8M5
3-(2-(p-tolyl)thiazole-4-carboxamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (78%
yield). 1H NMR (300 MHz, DMSO) δ 12.96 (s, 1H), 10.42 (s, 1H), 8.50 (t, J = 1.9 Hz,
1H), 8.46 (s, 1H), 8.13 (dt, J = 8.0, 1.6 Hz, 1H), 8.10 – 8.04 (m, 2H), 7.71 (dt, J = 7.7, 1.3
Hz, 1H), 7.50 (t, J = 7.9 Hz, 1H), 7.38 (d, J = 8.0 Hz, 2H), 2.39 (s, 3H). 13C NMR (151
MHz, DMSO) δ 21.08, 121.45, 124.63, 124.82, 125.15, 126.69, 128.90, 129.81, 129.84,
131.63, 138.69, 140.91, 150.12, 159.30, 167.55. HPLC: TR = 4.170 min, peak area =
99.2%. MP: 257.2-259.2 °C. HRMS m/z: [M + H]+ Calcd. for C18H14N2O3S 339.0798;
Found 339.0783, Error -4.4 ppm.

SMI-8M7
3-(2-(4-methoxyphenyl)thiazole-4-carboxamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (63%
yield). 1H NMR (600 MHz, DMSO) δ 13.03 (s, 1H), 10.42 (s, 1H), 8.50 (d, J = 1.9 Hz,
1H), 8.41 (s, 1H), 8.12 (dd, J = 7.3, 5.0 Hz, 3H), 7.71 (d, J = 7.6 Hz, 1H), 7.50 (t, J = 7.9
Hz, 1H), 7.11 (d, J = 8.7 Hz, 2H), 3.85 (s, 3H). 13C NMR (151 MHz, DMSO) δ 55.50,
114.58, 121.40, 124.62, 124.71, 124.78, 125.22, 128.43, 128.94, 131.31, 138.73, 149.98,
159.34, 161.39, 167.25, 167.34. HPLC: TR = 4.076 min, peak area = 97.3%. MP: 267.8269.0 °C. HRMS m/z: [M + H]+ Calcd. for C18H14N2O4S 355.0747 ; Found 355.0730,
Error -4.8 ppm.

126

SMI-8M8
3-(2-(benzo[d][1,3]dioxol-5-yl)thiazole-4-carboxamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (75%
yield). 1H NMR (600 MHz, DMSO) δ 13.03 (s, 1H), 10.41 (s, 1H), 8.49 (t, J = 2.0 Hz,
1H), 8.41 (s, 1H), 8.15 – 8.11 (m, 1H), 7.87 (d, J = 1.7 Hz, 1H), 7.71 (d, J = 7.7 Hz, 1H),
7.64 (dd, J = 8.2, 1.8 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.08 (d, J = 8.1 Hz, 1H), 6.15 (s,
2H). 13C NMR (151 MHz, DMSO) δ 101.92, 106.71, 108.82, 121.43, 121.62, 124.77,
124.82, 124.87, 126.81, 128.94, 128.96, 131.31, 138.70, 148.20, 149.57, 149.75, 159.23,
167.06, 167.25. HPLC: TR = 3.893 min, peak area = 96.9%. MP: 279.7-281.0 °C. HRMS
m/z: [M + H]+ Calcd. for C18H12N2O5S 369.0540; Found 369.0533, Error -1.8 ppm.

SMI-8H1
3-(2-(2-(benzo[d][1,3]dioxol-5-yl)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (61%
yield).1H NMR (600 MHz, DMSO) δ 12.99 (s, 1H), 10.45 (s, 1H), 8.30 (s, 1H), 7.84 (dd,
J = 8.0, 2.1 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.42 (td, J = 7.8, 4.1 Hz, 4H), 7.25 (t, J =
7.5 Hz, 2H), 7.21 – 7.09 (m, 3H), 7.01 (d, J = 8.1 Hz, 1H), 6.10 (s, 2H), 4.03 (dd, J = 8.9,
6.1 Hz, 1H), 2.65 (td, J = 7.4, 4.0 Hz, 2H), 2.12 – 2.02 (m, 1H), 1.92 (dq, J = 13.8, 7.1
Hz, 1H), 1.62 (p, J = 7.6 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 29.22, 31.58, 34.87,
49.09, 101.78, 105.92, 108.90, 114.79, 120.03, 120.71, 123.37, 124.24, 125.76, 127.44,
128.33, 129.10, 131.35, 139.30, 141.96, 148.07, 149.00, 155.62, 166.10, 167.18, 170.79.
HPLC: TR = 3.880 min, peak area = 100.0%. MP: 206.5-208.4 °C. HRMS m/z: [M + H]+
Calcd. for C28H24N2O5S 501.1479; Found 504.1467, Error -2.3 ppm.

127

SMI-8H2
3-(5-phenyl-2-(2-(thiophen-3-yl)thiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (83%
yield). 1H NMR (600 MHz, CDCl3) δ 8.15 – 8.10 (m, 23H), 7.90 (dt, J = 2.8, 1.1 Hz,
10H), 7.78 (dt, J = 7.7, 1.3 Hz, 11H), 7.56 (dq, J = 5.2, 1.2 Hz, 11H), 7.50 – 7.35 (m,
22H), 7.25 – 7.22 (m, 19H), 7.20 – 7.10 (m, 44H), 4.26 – 3.64 (m, 12H), 3.07 – 2.46 (m,
24H), 2.26 (dddd, J = 12.9, 10.5, 7.2, 5.4 Hz, 11H), 2.03 (tq, J = 13.3, 6.3 Hz, 11H), 1.75
(dddd, J = 15.1, 11.1, 9.0, 5.8 Hz, 11H), 1.71 – 1.59 (m, 8H). 13C NMR (151 MHz,
CDCl3) δ 29.30, 33.27, 35.50, 50.11, 114.65, 121.11, 124.43, 124.71, 125.31, 125.79,
126.10, 127.18, 128.29, 128.37, 129.23, 130.31, 134.48, 138.68, 141.79, 154.65, 164.16,
170.24, 170.58. HPLC: TR = 3.898 min, peak area = 99.5%. MP: 82.0-83.9 °C. HRMS
m/z: [M + H]+ Calcd. for C25H22N2O3S2 463.1145; Found 463.1127, Error -3.8 ppm.

SMI-8H3
3-(2-(2-(4-isobutylphenyl)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (65%
yield). 1H NMR (600 MHz, CDCl3) δ 9.64 (s, 1H), 8.15 (s, 1H), 8.11 – 7.98 (m, 1H), 7.87
(d, J = 7.9 Hz, 2H), 7.81 – 7.72 (m, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.27 (s, 1H), 7.25 –
7.22 (m, 3H), 7.15 (dd, J = 9.1, 7.3 Hz, 3H), 7.10 (s, 1H), 3.91 (t, J = 7.6 Hz, 1H), 2.89 –
2.58 (m, 2H), 2.53 (d, J = 7.2 Hz, 2H), 2.41 – 2.17 (m, 1H), 2.07 (dtd, J = 15.5, 8.6, 5.1
Hz, 1H), 1.90 (dq, J = 13.5, 6.8 Hz, 1H), 1.83 – 1.48 (m, 2H), 0.92 (d, J = 6.6 Hz, 6H).
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C NMR (151 MHz, CDCl3) δ 22.30, 29.32, 30.13, 33.43, 35.50, 45.20, 50.53, 115.17,
121.12, 124.60, 125.37, 125.79, 126.42, 128.30, 128.38, 129.20, 129.85, 130.16, 130.34,
138.63, 141.82, 144.79, 154.56, 169.63, 170.64, 170.67. HPLC: TR = 4.709 min, peak
area = 99.8%. MP: 175.6-176.5 °C. HRMS m/z: [M + H]+ Calcd. for C31H32N2O3S
513.2206; Found 513.2226, Error 3.8 ppm.

SMI_8H4
3-(5-phenyl-2-(thiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford an off-white solid (84% yield).
1
H NMR (300 MHz, DMSO) δ 12.97 (s, 1H), 10.41 (s, 1H), 9.04 (d, J = 2.0 Hz, 1H),
8.27 (t, J = 1.9 Hz, 1H), 7.83 (ddd, J = 8.1, 2.3, 1.1 Hz, 1H), 7.62 (dt, J = 7.8, 1.3 Hz,
1H), 7.50 (d, J = 2.0 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.34 – 7.21 (m, 2H), 7.20 – 6.99
(m, 3H), 4.06 (dd, J = 8.9, 6.1 Hz, 1H), 2.63 (t, J = 7.6 Hz, 2H), 1.97 (dtd, J = 50.5, 13.8,
7.5 Hz, 2H), 1.58 (p, J = 7.6 Hz, 2H). 13C NMR (75 MHz, DMSO) δ 29.15, 31.50, 34.84,
48.85, 114.98, 119.96, 123.29, 124.15, 125.73, 128.27, 128.30, 129.02, 131.32, 139.27,
141.92, 153.66, 155.65, 167.14, 170.82. HPLC: TR = 3.904 min, peak area = 97.2%. MP:
173.2-175.7 °C. HRMS m/z: [M + H]+ Calcd. for C21H20N2O3S 381.1267; Found
381.1269, Error 0.4 ppm.
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SMI-8H5
3-(5-phenyl-2-(2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (61%
yield). 1H NMR (600 MHz, DMSO) δ 13.00 (s, 1H), 10.50 (s, 1H), 8.31 (d, J = 1.9 Hz,
1H), 8.11 (d, J = 8.2 Hz, 2H), 7.88 – 7.83 (m, 4H), 7.76 – 7.55 (m, 2H), 7.43 (t, J = 7.9
Hz, 1H), 7.25 (t, J = 7.5 Hz, 2H), 7.20 – 6.96 (m, 4H), 4.11 (dd, J = 8.9, 6.2 Hz, 1H),
2.71 – 2.60 (m, 2H), 2.16 – 2.06 (m, 1H), 2.02 – 1.79 (m, 1H), 1.63 (p, J = 7.7 Hz, 2H).
13
C NMR (151 MHz, DMSO) δ 29.20, 31.65, 34.86, 49.07, 117.29, 120.04, 123.14,
123.38, 124.28, 124.95, 125.77, 126.25, 126.27, 126.30, 126.32, 126.74, 128.32, 129.10,
129.57, 129.78, 130.00, 130.21, 131.35, 136.53, 139.26, 141.92, 156.52, 164.58, 167.16,
170.65. HPLC: TR = 4.062 min, peak area = 98.9%. MP: 143.4-145.2 °C. HRMS m/z: [M
+ H]+ Calcd. for C28H23F3N2O3S 525.1454; Found 525.1428, Error -5.0 ppm.

SMI-8H6
3-(2-(2-(4-methoxyphenyl)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford an off-white solid (60% yield).
1
H NMR (300 MHz, DMSO) δ 12.98 (s, 1H), 10.46 (s, 1H), 8.30 (t, J = 1.9 Hz, 1H), 7.84
(d, J = 8.8 Hz, 3H), 7.63 (dt, J = 7.8, 1.3 Hz, 1H), 7.54 – 7.33 (m, 2H), 7.25 (dd, J = 8.1,
6.7 Hz, 2H), 7.21 – 7.10 (m, 3H), 7.03 (d, J = 8.8 Hz, 2H), 4.05 (dd, J = 8.9, 6.0 Hz, 1H),
3.80 (s, 3H), 2.65 (dd, J = 8.7, 6.5 Hz, 2H), 2.07 (dt, J = 15.7, 8.1 Hz, 1H), 1.94 (dt, J =
13.7, 6.5 Hz, 1H), 1.62 (p, J = 7.6 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 29.24, 31.58,
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34.88, 49.11, 55.39, 114.42, 114.59, 120.01, 123.33, 124.22, 125.76, 125.90, 127.63,
128.33, 129.08, 131.41, 139.31, 141.97, 155.71, 160.81, 166.34, 167.21, 170.83. HPLC:
TR = 4.027 min, peak area = 100.0%. MP: 174.9-176.8 °C. HRMS m/z: [M + H]+ Calcd.
for C28H26N2O4S 487.1686; Found 487.1677, Error -1.9 ppm.

SMI-8H7
3-(2-(2-(furan-3-yl)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a slightly yellow-white solid
(15% yield). 1H NMR (600 MHz, DMSO) δ 12.98 (s, 1H), 10.47 (s, 1H), 8.28 (t, J = 1.9
Hz, 1H), 7.86 (dd, J = 1.8, 0.8 Hz, 1H), 7.83 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H), 7.62 (dt, J =
7.8, 1.3 Hz, 1H), 7.48 (s, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.25 (dd, J = 8.0, 7.1 Hz, 2H),
7.22 – 7.11 (m, 3H), 7.04 (dd, J = 3.5, 0.8 Hz, 1H), 6.68 (dd, J = 3.5, 1.8 Hz, 1H), 4.04
(dd, J = 9.0, 6.0 Hz, 1H), 2.64 (td, J = 7.3, 5.4 Hz, 2H), 2.14 – 1.98 (m, 1H), 1.99 – 1.81
(m, 1H), 1.60 (p, J = 7.6 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 29.21, 31.63, 34.83,
48.97, 109.12, 112.62, 114.78, 119.96, 123.32, 124.23, 125.76, 128.31, 128.33, 129.10,
131.31, 139.25, 141.93, 144.76, 148.18, 155.95, 156.46, 167.13, 170.65. HPLC: TR =
4.433 min, peak area = 99.3%. MP: 90.0-93.2 °C. HRMS m/z: [M + H]+ Calcd. for
C25H22N2O4S 447.1373; Found 447.1377, Error 0.9 ppm.
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SMI-8H8
3-(5-phenyl-2-(2-(p-tolyl)thiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (57%
yield). 1H NMR (600 MHz, CDCl3) δ 9.66 (s, 1H), 8.15 (s, 1H), 8.06 – 8.04 (m, 1H), 7.84
(d, J = 8.1 Hz, 2H), 7.78 (dd, J = 7.7, 1.1 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.28 (d, J =
7.9 Hz, 2H), 7.26 – 7.22 (m, 2H), 7.19 – 7.12 (m, 3H), 7.11 (s, 1H), 4.28 – 3.86 (m, 1H),
2.82 – 2.54 (m, 2H), 2.40 (s, 3H), 2.37 – 2.21 (m, 1H), 2.06 (dddd, J = 13.4, 10.2, 8.3, 5.1
Hz, 1H), 1.83 – 1.56 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 21.44, 29.32, 33.40, 35.50,
50.51, 115.15, 121.09, 124.55, 125.35, 125.79, 126.54, 128.30, 128.38, 129.20, 129.81,
130.10, 130.14, 138.63, 140.98, 141.82, 154.59, 169.60, 170.64. HPLC: TR = 4.811 min,
peak area = 100.0%. MP: 179.1-182.3 °C. HRMS m/z: [M + H]+ Calcd. for C28H26N2O3S
471.1737; Found 471.1719, Error -3.8 ppm.

SMI-8H9
3-(2-(2-(3-chlorophenyl)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford an off-white solid (50% yield).
1
H NMR (600 MHz, CDCl3) δ 11.92 (s, 1H), 9.39 (s, 1H), 8.12 (s, 1H), 8.08 – 8.01 (m,
1H), 7.96 (s, 1H), 7.93 – 7.70 (m, 2H), 7.48 – 7.36 (m, 3H), 7.26 – 7.23 (m, 2H), 7.19 (s,
1H), 7.18 – 7.12 (m, 3H), 3.98 – 3.92 (m, 1H), 2.73 – 2.62 (m, 2H), 2.32 – 2.24 (m, 1H),
2.11 – 2.02 (m, 1H), 1.83 – 1.71 (m, 1H), 1.70 – 1.62 (m, 1H). 13C NMR (75 MHz,
DMSO) δ 29.14, 31.59, 34.82, 49.03, 116.66, 120.03, 123.35, 124.24, 124.82, 125.30,
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125.74, 128.29, 129.06, 129.88, 131.25, 131.36, 133.96, 134.88, 139.23, 141.91, 156.15,
164.56, 167.13, 170.64. HPLC: TR = 4.274 min, peak area = 96.7%. HRMS m/z: [M +
H]+ Calcd. for C27H23ClN2O3S 491.1191; Found 491.1183, Error -1.6 ppm.

SMI-8H10
3-(2-(2-(3,4-difluorophenyl)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (67%
yield). 1H NMR (600 MHz, DMSO) δ 13.26 – 12.57 (m, 1H), 10.46 (s, 1H), 8.29 (s, 1H),
8.02 – 7.88 (m, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.81 – 7.71 (m, 1H), 7.62 (d, J = 7.7 Hz,
1H), 7.56 (d, J = 13.7 Hz, 2H), 7.42 (t, J = 8.0 Hz, 1H), 7.25 (t, J = 7.5 Hz, 2H), 7.23 –
7.10 (m, 3H), 4.07 (t, J = 7.3 Hz, 1H), 2.66 (t, J = 5.8 Hz, 2H), 2.08 (dq, J = 15.5, 8.1 Hz,
1H), 1.94 (dq, J = 14.0, 7.0 Hz, 1H), 1.62 (p, J = 7.7 Hz, 2H). 13C NMR (151 MHz,
DMSO) δ 29.18, 31.61, 34.85, 40.06, 49.02, 114.94, 115.06, 116.72, 118.54, 118.65,
120.04, 123.22, 123.26, 123.29, 123.33, 124.26, 125.77, 128.32, 129.07, 130.58, 130.62,
130.64, 131.44, 139.24, 141.93, 148.94, 149.02, 149.65, 149.73, 150.57, 150.66, 151.30,
151.39, 156.10, 163.95, 167.22, 170.65. HPLC: TR = 4.741 min, peak area = 100.0%.
MP: 177.0-180.0 °C. HRMS m/z: [M + H]+ Calcd. for C27H22F2N2O3S 493.1392; Found
493.1370, Error -4.5 ppm.
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SMI-8H11
3-(5-phenyl-2-(2-phenylthiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (74%
yield). 1H NMR (600 MHz, CDCl3) δ 9.57 (s, 1H), 8.14 (t, J = 1.9 Hz, 1H), 8.02 (ddd, J =
8.3, 2.3, 1.1 Hz, 1H), 8.00 – 7.91 (m, 2H), 7.78 (dt, J = 7.7, 0.8 Hz, 1H), 7.56 – 7.44 (m,
3H), 7.41 (t, J = 7.9 Hz, 1H), 7.24 (d, J = 7.4 Hz, 2H), 7.19 – 7.06 (m, 4H), 4.16 – 3.69
(m, 1H), 2.89 – 2.52 (m, 2H), 2.48 – 2.17 (m, 1H), 2.21 – 1.96 (m, 1H), 1.92 – 1.53 (m,
2H). 13C NMR (151 MHz, CDCl3) δ 29.32, 33.42, 35.49, 50.55, 115.68, 121.08, 124.62,
125.44, 125.81, 126.61, 128.31, 128.38, 129.14, 129.22, 130.13, 130.60, 132.74, 138.58,
141.80, 154.78, 169.39, 170.60, 170.65. HPLC: TR = 4.083 min, peak area = 99.7%. MP:
156.5-158.8 °C. HRMS m/z: [M + H]+ Calcd. for C27H24N2O3S 457.1580; Found
457.1576, Error -1.0 ppm.

SMI-8H12
3-(5-phenyl-2-(2-(o-tolyl)thiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (62%
yield). 1H NMR (300 MHz, CDCl3) δ 9.50 (s, 1H), 8.41 – 7.96 (m, 2H), 7.96 – 7.59 (m,
2H), 7.46 – 7.27 (m, 5H), 7.26 – 7.10 (m, 5H), 4.10 (s, 1H), 2.88 – 2.59 (m, 2H), 2.56 (s,
3H), 2.44 – 2.21 (m, 1H), 2.15 – 1.99 (m, 1H), 1.86 – 1.60 (m, 2H). 13C NMR (151 MHz,
DMSO) δ 21.16, 29.19, 31.35, 34.90, 49.04, 115.93, 120.03, 123.37, 124.19, 125.75,
126.41, 128.32, 129.06, 129.41, 129.53, 131.30, 131.61, 132.35, 135.83, 139.33, 141.96,
155.28, 166.06, 167.16, 170.79. HPLC: TR = 4.728 min, peak area = 100.0%. MP: 126.5-
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130.1 °C. HRMS m/z: [M + H]+ Calcd. for C28H26N2O3S 471.1737; Found 471.1733,
Error -0.8 ppm.

SMI-8H13
3-(2-(2-(furan-2-yl)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (99%
yield). 1H NMR (300 MHz, CDCl3) δ 9.55 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 8.14 (t, J =
1.8 Hz, 1H), 8.02 – 7.68 (m, 1H), 7.70 – 7.47 (m, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.24 (d, J
= 7.2 Hz, 1H), 7.21 – 7.13 (m, 4H), 7.10 (dd, J = 3.5, 0.7 Hz, 1H), 6.56 (dd, J = 3.5, 1.8
Hz, 1H), 4.07 (t, J = 7.6 Hz, 1H), 2.67 (q, J = 7.2 Hz, 2H), 2.25 (dt, J = 13.0, 6.0 Hz, 1H),
1.85 – 1.58 (m, 2H). 13C NMR (151 MHz, DMSO) δ 29.22, 31.64, 34.84, 48.98, 109.12,
112.62, 114.77, 119.98, 123.33, 124.25, 125.76, 128.31, 128.33, 129.10, 131.32, 139.26,
141.93, 144.75, 148.19, 155.96, 156.48, 167.15, 170.66. HPLC: TR = 3.914 min, peak
area = 95.9%. MP: 91.0-94.2 °C. HRMS m/z: [M + H]+ Calcd. for C25H22N2O4S
447.1373; Found 447.1356, Error -3.8 ppm.
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SMI-8H14
3-(2-(2-(4-chlorophenyl)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a white solid (56% yield). 1H
NMR (600 MHz, CDCl3) δ 11.70 (s, 1H), 9.40 (s, 1H), 8.11 (d, J = 2.0 Hz, 1H), 8.03 (d,
J = 8.1 Hz, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.79 (dt, J = 7.8, 1.2 Hz, 1H), 7.45 (d, J = 8.5
Hz, 2H), 7.41 (t, J = 8.0 Hz, 1H), 7.24 (d, J = 7.5 Hz, 2H), 7.17 (s, 1H), 7.16 – 7.09 (m,
3H), 3.94 (t, J = 7.6 Hz, 1H), 3.03 – 2.50 (m, 2H), 2.33 – 2.22 (m, 1H), 2.06 (dddd, J =
13.5, 10.4, 8.3, 5.2 Hz, 1H), 1.81 – 1.61 (m, 2H). 13C NMR (151 MHz, DMSO) δ 29.50,
33.51, 35.68, 50.79, 116.18, 121.28, 124.86, 125.70, 126.04, 128.01, 128.53, 128.58,
129.49, 129.58, 130.23, 131.47, 136.79, 138.69, 141.95, 155.24, 168.20, 170.63, 170.76.
HPLC: TR = 4.195 min, peak area = 89.2%. MP: 172.0-177.4 °C. HRMS m/z: [M + H]+
Calcd. for C27H23ClN2O3S 491.1191; Found 491.1176, Error -3.0 ppm.

SMI8H15
3-(2-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)thiazol-4-yl)-5phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (79%
yield). 1H NMR (600 MHz, CDCl3) δ 12.72 (s, 1H), 9.76 (s, 1H), 8.19 (s, 1H), 8.04 (d, J
= 8.0 Hz, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 2.2 Hz, 1H), 7.45 – 7.42 (m, 1H),
7.40 (t, J = 7.9 Hz, 1H), 7.24 (t, J = 7.6 Hz, 2H), 7.21 – 7.12 (m, 3H), 7.08 (s, 1H), 6.94
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(d, J = 8.4 Hz, 1H), 4.30 (s, 4H), 3.93 (s, 1H), 3.05 – 2.51 (m, 2H), 2.52 – 2.16 (m, 1H),
2.05 (dddd, J = 13.4, 10.3, 8.3, 5.1 Hz, 1H), 1.96 – 1.51 (m, 2H). 13C NMR (151 MHz,
CDCl3) δ 29.30, 33.42, 35.48, 50.45, 64.28, 64.55, 114.91, 115.57, 117.92, 120.13,
121.07, 124.50, 125.32, 125.79, 126.28, 128.30, 128.37, 129.19, 130.15, 138.61, 141.81,
143.92, 145.90, 154.24, 169.03, 170.60, 170.86. HPLC: TR = 3.972 min, peak area =
99.2%. MP: 86.4-88.2 °C. HRMS m/z: [M + H]+ Calcd. for C29H26N2O5S 515.1635;
Found 515.1629, Error -1.2 ppm.

SMI-8H16
3-(5-phenyl-2-(2-((pyridin-3-ylmethyl)amino)thiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford a yellow solid (47% yield). 1H
NMR (300 MHz, DMSO) δ 10.16 (s, 1H), 8.56 (s, 1H), 8.44 (d, J = 4.3 Hz, 1H), 8.24 (s,
1H), 8.11 (s, 1H), 7.92 – 7.61 (m, 3H), 7.33 (s, 1H), 7.30 – 7.20 (m, 3H), 7.16 (d, J = 7.3
Hz, 3H), 6.36 (s, 1H), 4.42 (d, J = 5.8 Hz, 2H), 3.66 (dd, J = 8.7, 6.1 Hz, 1H), 2.60 (t, J =
7.6 Hz, 2H), 1.84 (ddd, J = 31.2, 13.3, 6.0 Hz, 2H), 1.56 (q, J = 7.6 Hz, 2H). 13C NMR
(151 MHz, DMSO) δ 29.21, 30.89, 34.90, 45.32, 49.23, 101.38, 119.90, 123.24, 123.38,
124.04, 125.71, 128.30, 129.01, 131.29, 134.62, 135.45, 139.38, 142.02, 148.26, 149.10,
150.51, 167.19, 168.08, 170.95. HPLC: TR = 4.463 min, peak area = 65.8%. MP: 155.8160.0 °C. HRMS m/z: [M + H]+ Calcd. for C27H26N4O3S 487.1798; Found 487.1798,
Error 0.0 ppm.
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SMI-H17
3-(5-phenyl-2-(2-(phenylamino)thiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford a yellow solid (57% yield). 1H
NMR (600 MHz, DMSO) δ 10.31 (s, 1H), 10.17 (s, 1H), 8.22 (s, 1H), 7.82 (dt, J = 8.1,
1.6 Hz, 1H), 7.59 (t, J = 7.2 Hz, 3H), 7.37 (t, J = 7.9 Hz, 1H), 7.29 – 7.22 (m, 4H), 7.21 –
7.18 (m, 2H), 7.18 – 7.13 (m, 1H), 6.90 (t, J = 7.3 Hz, 1H), 6.60 (s, 1H), 3.81 (dd, J =
9.2, 5.8 Hz, 1H), 2.65 (td, J = 7.4, 3.9 Hz, 2H), 2.05 – 1.96 (m, 1H), 1.91 – 1.83 (m, 1H),
1.62 (p, J = 7.7 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 29.18, 30.52, 34.89, 49.18,
102.90, 116.72, 119.96, 121.06, 123.29, 124.08, 125.74, 128.32, 128.89, 129.04, 131.30,
139.41, 141.23, 142.00, 150.64, 162.87, 167.18, 170.87. HPLC: TR = 3.999 min, peak
area = 93.6%. MP: 222.2-225.6 °C. HRMS m/z: [M + H]+ Calcd. for C27H25N3O3S
472.1689; Found 472.1685, Error -0.9 ppm.

SMI-8H18
3-(2-(2-((4-methoxyphenyl)amino)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (47%
yield). 1H NMR (600 MHz, DMSO) δ 13.04 (s, 1H), 10.32 (s, 1H), 9.94 (s, 1H), 8.26 (t, J
= 2.0 Hz, 1H), 7.93 – 7.80 (m, 1H), 7.61 (dt, J = 7.7, 1.4 Hz, 1H), 7.52 – 7.46 (m, 2H),
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7.40 (t, J = 7.9 Hz, 1H), 7.26 (t, J = 7.6 Hz, 2H), 7.23 – 7.18 (m, 2H), 7.18 – 7.13 (m,
1H), 6.84 – 6.78 (m, 2H), 6.53 – 6.50 (m, 1H), 3.77 (dd, J = 9.1, 5.8 Hz, 1H), 3.69 (s,
3H), 2.65 (td, J = 7.3, 4.4 Hz, 2H), 2.04 – 1.95 (m, 1H), 1.90 – 1.81 (m, 1H), 1.61 (p, J =
7.3 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 29.20, 30.45, 34.91, 40.06, 49.20, 55.18,
102.05, 114.09, 118.60, 119.95, 123.21, 124.05, 125.73, 128.32, 129.00, 134.76, 139.43,
142.02, 150.59, 153.99, 163.62, 170.90. HPLC: TR = 4.074 min, peak area = 98.6%. MP:
258.0-259.8 °C. HRMS m/z: [M + H]+ Calcd. for C28H27N3O4S 502.1795; Found
502.1792, Error -0.6 ppm.

SMI-8H19
3-(2-(2-((4-chlorophenyl)amino)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a white solid (49% yield).1H
NMR (600 MHz, DMSO) δ 13.00 (s, 1H), 10.36 (s, 1H), 10.31 (s, 1H), 8.28 (d, J = 2.2
Hz, 1H), 8.00 – 7.77 (m, 1H), 7.78 – 7.55 (m, 3H), 7.43 (t, J = 7.9 Hz, 1H), 7.26 (dd, J =
8.2, 5.8 Hz, 4H), 7.22 – 7.18 (m, 2H), 7.17 – 7.13 (m, 1H), 6.65 (s, 1H), 3.81 (dd, J = 9.2,
5.8 Hz, 1H), 2.65 (q, J = 7.1 Hz, 2H), 2.17 – 1.95 (m, 1H), 1.94 – 1.79 (m, 1H), 1.62 (p, J
= 7.7 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 29.18, 30.52, 34.90, 49.17, 103.45,
118.16, 119.97, 123.32, 124.10, 124.32, 125.74, 128.32, 128.67, 129.06, 131.31, 139.41,
140.15, 142.00, 150.67, 162.49, 167.19, 170.82. HPLC: TR = 4.664 min, peak area =
98.1%. MP: 262.0-263.5 °C. HRMS m/z: [M + H]+ Calcd. for C27H24ClN3O3S 506.1300;
Found 506.1286, Error -2.7 ppm.
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SMI-8H20
3-(2-(2-((3-chlorophenyl)amino)thiazol-4-yl)-5-phenylpentanamido)benzoic acid
Prepared to the general saponification procedure to afford a bright white solid (47%
yield). 1H NMR (600 MHz, DMSO) δ 10.42 (s, 1H), 10.33 (s, 1H), 8.20 (s, 1H), 7.86 (s,
1H), 7.82 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.44 (dd, J = 8.3, 2.1 Hz, 1H),
7.34 (t, J = 7.9 Hz, 1H), 7.25 (dd, J = 8.9, 7.5 Hz, 3H), 7.21 – 7.11 (m, 2H), 7.17 – 7.05
(m, 1H), 6.93 (dd, J = 8.0, 2.0 Hz, 1H), 6.68 (s, 1H), 3.84 (dd, J = 9.1, 5.8 Hz, 1H), 3.44
(s, 1H), 2.66 (q, J = 7.2 Hz, 2H), 2.06 – 1.95 (m, 1H), 1.92 – 1.83 (m, 1H), 1.62 (p, J =
7.6 Hz, 2H). 13C NMR (75 MHz, DMSO) δ 29.12, 30.49, 34.88, 49.05, 103.77, 115.07,
116.01, 120.02, 120.51, 123.30, 124.08, 125.72, 128.29, 128.97, 130.41, 131.32, 133.39,
139.35, 141.96, 142.52, 150.75, 162.26, 167.17, 170.82. HPLC: TR = 3.957 min, peak
area = 97.9%. MP: 258.9-259.7 °C. HRMS m/z: [M + H]+ Calcd. for C27H24ClN3O3S
506.1300; Found 506.1289, Error -2.1 ppm.
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SMI-8H21
3-(5-phenyl-2-(2-(p-tolylamino)thiazol-4-yl)pentanamido)benzoic acid
Prepared to the general saponification procedure to afford an off-white solid (60%
yield).1H NMR (600 MHz, DMSO) δ 10.18 (s, 1H), 8.18 (s, 1H), 8.04 (t, J = 5.9 Hz, 1H),
7.74 (dd, J = 8.0, 2.2 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.26 (t, J
= 7.5 Hz, 2H), 7.21 (d, J = 7.8 Hz, 2H), 7.19 – 7.13 (m, 3H), 7.05 (d, J = 7.7 Hz, 2H),
6.32 (s, 1H), 4.32 (dd, J = 6.0, 2.8 Hz, 2H), 3.66 (dd, J = 9.0, 6.0 Hz, 1H), 2.61 (td, J =
7.5, 3.9 Hz, 2H), 2.24 (s, 3H), 1.92 (dtd, J = 13.2, 8.8, 6.4 Hz, 1H), 1.83 – 1.74 (m, 1H),
1.56 (p, J = 7.1 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 20.70, 29.22, 30.86, 34.90,
47.59, 49.27, 100.90, 119.89, 119.96, 123.16, 124.01, 125.71, 127.61, 128.30, 128.79,
128.97, 131.43, 135.98, 136.03, 139.39, 142.04, 150.49, 167.22, 168.39, 170.98. HPLC:
TR = 4.422 min, peak area = 42.2%. MP: 160.9-163.0 °C. HRMS m/z: [M + H]+ Calcd.
for C29H29N3O3S 500.2002; Found 2009, Error 1.3 ppm.
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SMI-8H22
3-(5-phenyl-2-(2-((4-(trifluoromethyl)phenyl)amino)thiazol-4-yl)pentanamido)benzoic
acid
Prepared to the general saponification procedure to afford a yellow solid (38% yield). 1H
NMR (300 MHz, DMSO) δ 10.60 (s, 1H), 10.40 (s, 1H), 8.32 (s, 1H), 7.83 (t, J = 8.4 Hz,
3H), 7.69 (d, J = 8.7 Hz, 2H), 7.63 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.23 (dq,
J = 16.1, 7.9 Hz, 5H), 6.74 (s, 1H), 3.86 (t, J = 7.4 Hz, 1H), 2.67 (t, J = 7.5 Hz, 2H), 2.26
– 1.79 (m, 2H), 1.69 – 1.58 (m, 2H). 13C NMR (75 MHz, DMSO) δ 29.15, 30.64, 34.89,
49.09, 104.36, 115.77, 119.98, 122.66, 123.26, 124.12, 125.73, 128.31, 128.33, 129.00,
130.68, 131.42, 139.40, 142.00, 145.01, 150.82, 162.01, 167.08, 170.83. HPLC: TR =
4.216 min, peak area = 74.1%. MP: 231.2-237.2 °C. HRMS m/z: [M + Na]+ Calcd. for
C28H24F3N3O3S 562.1383; Found 532.1368, Error -2.6 ppm.
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APPENDIX B
1

H spectra, 13C spectra, and HPLC Chromatograms
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